HSCI 485 · Lesson 1

Psychedelics and Psychedelic-Assisted Therapy: Definitions, Effects and How to Weigh Claims

Psychedelic-Assisted Medicine: Science and Practice

Learning objectives for this lesson:

  1. Define the classic serotonergic psychedelics by their shared action at the serotonin 2A receptor, and distinguish them from the entactogen MDMA, the dissociative ketamine and the atypical agents ibogaine and salvinorin A.
  2. Explain why pharmacological groups, Canadian drug schedules and national survey categories sort the same substances in different ways.
  3. Describe psychedelic-assisted therapy as a phased process of screening, preparation, supervised dosing and integration, and contrast it with a daily medication and with supervised esketamine.
  4. Identify the authorized routes through which psychedelic-assisted therapy with a controlled substance can lawfully take place in Canada as of October 2026.
  5. Describe the perceptual, emotional, cognitive and self-related effects of psychedelics, and explain how the 5D-ASC, MEQ30, Ego Dissolution Inventory and Challenging Experience Questionnaire measure them.
  6. Explain what research scales, qualitative studies and user-reported sources such as PsychonautWiki can and cannot establish.
  7. Interpret Canadian and United States survey estimates of psychedelic use, including the effects of questionnaire changes, and summarize the evidence on microdosing, retreats and unlicensed storefronts.
  8. Explain the hype cycle as it has been applied to the growth of psychedelic research, and apply a six-item checklist (design, comparator, blinding, sample, follow-up and funding) to real claims from trial reports, company announcements, press releases and storefronts.

This course was developed by Dr. Kiffer G. Card.

Lesson 1 · HSCI 485

Psychedelics and Psychedelic-Assisted Therapy

Definitions, effects and how to weigh claims.

Psychedelic-Assisted Medicine: Science and Practice
Why start here

One word, many drugs, many kinds of claim

The word psychedelic is used for drugs that act on different targets, carry different risks and are regulated differently in Canada.

Claims about them range from randomized trials to storefront websites, and the two can sound alike.

The road map

Four sections

1 · Defining the field

Classes of psychedelics, legal and survey categories, and what makes a therapy psychedelic-assisted.

2 · Subjective effects

Research scales, user-reported sources and what each can establish.

3 · Patterns of use

Canadian and United States surveys, microdosing, retreats and storefronts.

4 · Weighing claims

The research era, the hype cycle and a six-item checklist.

Language and dates

How this course talks about psychedelics

  • The course uses person-first language, such as “people who use psychedelics”.
  • A difficult episode is a “challenging experience”; “bad trip” appears only as people’s own term.
  • “Hallucinogen” appears only as a legal or survey category.
  • User-reported sources are labelled as such, and regulatory facts carry a date.
Section 1 of 5

Defining the Field: Classes of Psychedelics and What Makes a Therapy Psychedelic-Assisted

⏱ Estimated reading time: 40 minutes
Section 1 of 5

Defining the Field

Classes of psychedelics, legal and survey categories, and what makes a therapy psychedelic-assisted.

The narrow definition

One receptor, three chemical families

Tryptamines

Psilocybin, psilocin and DMT.

Ergolines

LSD.

Phenethylamines

Mescaline.

All act as agonists or partial agonists at the serotonin 2A (5-HT2A) receptor (Nichols, 2016; Kelmendi et al., 2022).

The broad definition

A wider family and a crowded vocabulary

  • Atypical compounds produce related experiences through other mechanisms (Kelmendi et al., 2022).
  • Hallucinogen stresses perception, entheogen the spiritual, and entactogen or empathogen the social and emotional.
  • Nichols proposed “entactogen” for MDMA in 1986, from roots meaning “touching within” (Nichols, 2022).
Four groups

Grouping by primary mechanism

Classic psychedelics

Activate 5-HT2A receptors.

Entactogen: MDMA

Carried in by the serotonin transporter, which then releases serotonin.

Dissociative: ketamine

Inhibits NMDA glutamate receptors.

Atypical agents

Salvinorin A: kappa-opioid agonist. Ibogaine: many targets.

Other ways of sorting

Law and surveys use different categories

Controlled Drugs and Substances Act

As of October 2026: classic psychedelics in Schedule III; MDMA and ketamine in Schedule I; salvia in Schedule IV; ibogaine outside the Act, on the Prescription Drug List since 2017.

National surveys

The 2019 survey’s hallucinogens included PCP. The 2025 survey counts salvia with psychedelics and asks about dissociatives separately.

A different kind of treatment

Psychedelic-assisted therapy and daily medication

2dosing days in the psilocybin arm, with psychological support
42daily doses in the escitalopram arm of the same trial (Carhart-Harris et al., 2021)

An MDMA trial combined 3 preparatory, 3 eight-hour experimental and 9 integration sessions over about 18 weeks (Mitchell et al., 2021).

Carry forward

Lawful routes, and the experience itself

  • As of October 2026, Health Canada names three authorized routes: clinical trials, the Special Access Program and subsection 56(1) exemptions (Health Canada, 2025).
  • The same molecule in a trial comes with screening, support and follow-up; in a storefront it comes with none of these.
  • Next: how the experience is described and measured.

Introduction

Every claim in this course depends on knowing which substance is being discussed. The word “psychedelic” appears in news about mushroom storefronts, in reports of clinical trials for depression and in the names of companies that sell nasal sprays, and it is applied to drugs that act on quite different molecular targets. A reader who learns that “a psychedelic” helped people with post-traumatic stress disorder needs to know whether the trial used MDMA, psilocybin or ketamine, because the three drugs act differently, carry different risks and are regulated differently in Canada.

Part 1.1 separates the narrow pharmacological meaning of the word from its broader everyday use, and Part 1.2 sorts the substances into four groups by primary mechanism. Part 2.1 compares those groups with Canadian legal and survey categories. Part 3.1 explains what makes a treatment a psychedelic-assisted therapy, and Part 4.1 describes the routes through which such therapy can lawfully take place in Canada. HSCI 180 Lesson 7 introduced these drugs, and Lesson 3 of this course develops their pharmacology.

Learning Objectives

  • 1.1 Define the classic serotonergic psychedelics and explain why psilocybin, LSD, DMT and mescaline are grouped by their shared action at the serotonin 2A receptor.
  • 1.2 Distinguish entactogens, dissociatives and atypical agents from the classic psychedelics by their primary mechanism, using MDMA, ketamine, ibogaine and salvinorin A as examples.
  • 2.1 Explain why pharmacological groups, Canadian legal schedules and survey categories sort the same drugs in different ways.
  • 3.1 Describe the phases of psychedelic-assisted therapy and explain how this model of treatment differs from a daily medication and from supervised esketamine.
  • 4.1 Identify the authorized routes through which psychedelic-assisted therapy with a controlled substance can lawfully take place in Canada as of October 2026.

1.1 What Counts as a Psychedelic

The word psychedelic has a narrow meaning, used in pharmacology, and a broad one, used in clinics, newspapers and everyday speech. Both meanings appear in the research literature, so a careful reader checks which one an author intends.

The term comes from the Greek for “mind manifesting”, and it refers to the drugs’ subjective effects. The psychiatrist Humphry Osmond proposed it in 1956, in correspondence with the writer Aldous Huxley, and introduced it publicly in a medical paper in 1957 (Kelmendi et al., 2022; Dyck, 2019). Lesson 2 describes how the word entered psychiatry during the first period of psychedelic research.

1.1.1 The Narrow Definition: Classic Serotonergic Psychedelics

In its narrow sense, the word refers to the classic, or serotonergic, psychedelics. David Nichols (2016) describes them as powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes, and he reports a consensus that they act as agonists or partial agonists at the serotonin 2A receptor, usually written as the 5-HT2A receptor. An agonist is a molecule that binds to a receptor and activates it, much as the body’s own neurotransmitter would, and a partial agonist activates it less fully. The receptors that matter most sit on the long upper branches (apical dendrites) of pyramidal neurons in layer V of the neocortex (Nichols, 2016). Kelmendi and colleagues (2022) state that 5-HT2A receptors are essential for the subjective effects of these drugs. The two reviews agree on this account of the class, which Nichols describes as a consensus.

The classic psychedelics come from three chemical families (Kelmendi et al., 2022). The tryptamines, whose structure resembles serotonin itself, include psilocybin, its active metabolite psilocin, and N,N-dimethyltryptamine (DMT). The ergolines, made by chemically processing compounds first isolated from the ergot fungus, include lysergic acid diethylamide (LSD). The phenethylamines, built on a different scaffold of a benzene ring and a short amine chain, include mescaline. The three families look different on paper, yet all of them act through the same receptor, which is why researchers treat them as one pharmacological class. 3-D Model 1.1 lets you explore where this shared receptor is concentrated in the adult human brain, using a group-average map from positron emission tomography (PET), a scanning method that follows a weakly radioactive tracer that binds to the receptor.

3-D Model 1.1. The model shows a standard adult brain coloured by the density of 5-HT2A receptors, which is high across the cerebral cortex and very low in the cerebellum, and its menu switches to maps of other receptors and transporters. Receptor densities are group-average PET maps from Hansen and colleagues (2022), with the 5-HT2A map from Beliveau and colleagues (2017), shown on the MNI ICBM152 template brain.

1.1.2 The Broad Definition: Atypical Compounds

Several other drugs produce related psychological effects through different mechanisms. Kelmendi and colleagues (2022) call them atypical compounds and note that they are sometimes called psychedelics under a broader definition. The group includes MDMA, a phenethylamine that binds weakly or not at all to serotonin receptors, and a set of drugs the same authors call dissociatives: ketamine, phencyclidine (PCP), nitrous oxide, ibogaine and salvinorin A. Other authors sort these drugs differently: Mosca and colleagues (2023) describe ibogaine as a psychedelic with dissociative properties. This course places ketamine among the dissociatives and treats ibogaine and salvinorin A as a separate group of atypical agents, because each acts mainly through targets that neither the classic psychedelics nor ketamine share.

1.1.3 Other Words for the Same Drugs

The vocabulary is crowded because each word emphasizes a different part of the experience. Kelmendi and colleagues (2022) note that “hallucinogen” emphasizes perceptual effects, “entheogen” spiritual effects, and “empathogen” or “entactogen” social and emotional effects. Two further conventions apply in this course. The word hallucinogen is used only as a legal or survey category, since, as Section 3 shows, one Canadian survey’s hallucinogen category included the dissociative PCP alongside LSD and psilocybin. The phrase plant medicines is used only when describing how communities name their own ceremonial practices with plants such as peyote or ayahuasca.

The six cards below define the terms that recur most often; note which feature of the drug or experience each term picks out.

Classic psychedelicClick to explore
EntactogenClick to explore
EmpathogenClick to explore
DissociativeClick to explore
HallucinogenClick to explore
EntheogenClick to explore

Part 1.1 has distinguished a narrow class defined by one receptor from a broad family defined by similar experiences. Part 1.2 turns these definitions into four working groups, and Part 2.1 compares them with the ways Canadian law and Canadian surveys sort the same drugs.

1.2 Four Groups of Substances

For most purposes in this course, the substances fall into four groups: the classic psychedelics, the entactogen MDMA, the dissociative ketamine, and the atypical agents ibogaine and salvinorin A. Grouping by primary mechanism makes the later lessons easier to follow, because mechanism shapes effects, risks and drug interactions.

Table 1.1 lists eight substances with their natural source or origin, their group, their primary mechanism and their status under the Controlled Drugs and Substances Act (CDSA), Canada’s main drug control statute. Figure 1.1 then shows the four primary molecular targets side by side.

Table 1.1. Eight substances discussed in this course, with their source, group, primary mechanism and status under the Controlled Drugs and Substances Act as consolidated to 30 September 2026.

SubstanceSource or originGroupPrimary mechanismStatus in Canada
Psilocybin and psilocinA few hundred species of mushrooms (Kelmendi et al., 2022)Classic psychedelic (tryptamine)Psilocybin is a prodrug converted to psilocin in the gut lining and liver; psilocin activates 5-HT2A receptorsCDSA Schedule III
LSDMade from compounds first isolated from the ergot fungusClassic psychedelic (ergoline)Activates 5-HT2A receptorsCDSA Schedule III
DMTMany plants; a component of the Amazonian brew ayahuascaClassic psychedelic (tryptamine)Activates 5-HT2A receptors; inactive when swallowed unless monoamine oxidase is inhibitedCDSA Schedule III
MescalinePeyote and San Pedro cacti (Kelmendi et al., 2022)Classic psychedelic (phenethylamine)Activates 5-HT2A receptorsCDSA Schedule III, with the entry reading “but not peyote”
MDMASyntheticEntactogenCarried into neurons by the serotonin transporter, which then releases stored serotonin (Nichols, 2022)CDSA Schedule I, listed among the amphetamines
KetamineSynthetic anaesthetic in clinical use since 1970 (Zanos et al., 2018)DissociativeInhibits NMDA glutamate receptors (Zanos et al., 2018)CDSA Schedule I, listed under phencyclidine and its derivatives
IbogaineRoot of the West African shrub Tabernanthe iboga, a sacrament in the Bwiti religion (Mosca et al., 2023)Atypical agentMany targets, including monoamine transporters and NMDA, nicotinic and 5-HT2A receptors; its metabolite noribogaine activates kappa-opioid receptors (Mosca et al., 2023)Outside the CDSA; added to Health Canada’s Prescription Drug List on 19 May 2017
Salvinorin ALeaves of Salvia divinorum, used in Mazatec spiritual practice in Oaxaca, Mexico (Roth et al., 2002)Atypical agentSelective kappa-opioid receptor agonist with no action at 5-HT2A receptors (Roth et al., 2002)CDSA Schedule IV (Salvia divinorum and its preparations, in force from February 2016)

Two entries need comment. Psilocybin is a prodrug, a compound that becomes active only after the body converts it (Kelmendi et al., 2022), so studies of psilocybin are in practice studies of psilocin; Lesson 3 explains this and the pharmacology of ayahuasca. Ibogaine was added to the Prescription Drug List after Health Canada received reports of serious adverse reactions, so that its sale could be restricted to prescription (Health Canada, 2017); Lesson 6 examines its cardiac risks.

Classicpsychedelics Entactogen(MDMA) Dissociative(ketamine) Atypical agents(ibogaine, salvinorin A) Serotonin 2A(5-HT2A) receptor Activated by the drug(agonist orpartial agonist) Serotonintransporter Carries MDMA intothe neuron, thenreleases serotonin NMDA glutamatereceptor Inhibited bythe drug Kappa-opioidreceptor Salvinorin A: selectiveagonist. Ibogaine:many targets Psilocybin, LSD,DMT, mescaline MDMA Ketamine(and esketamine) Ibogaine andnoribogaine; salvinorin A Each drug also has weaker actions at other targets (Lesson 3).
Figure 1.1. The primary molecular target of each group of substances, drawn from Nichols (2016), Nichols (2022), Zanos and colleagues (2018), Roth and colleagues (2002) and Mosca and colleagues (2023). The diagram simplifies the pharmacology to one main target per group.

Interactive 1.1 asks you to sort the eight substances yourself. For each one, choose its group and its primary mechanism, then check your answers against Table 1.1 and the feedback, which gives the source for each placement.

Interactive 1.1
Sort substances by group and primary mechanism
Choose a group and a primary mechanism for each substance, then select “Check my sorting”. Each row is marked correct only when both choices match the sources cited in Table 1.1.

2.1 Legal Schedules and Survey Categories Sort the Same Drugs Differently

Pharmacological groups are only one way of sorting these drugs, and Canadian law and Canadian surveys use others. The CDSA does not follow pharmacology: as of October 2026, its consolidated text places the classic psychedelics in Schedule III, while MDMA and ketamine sit in Schedule I, the schedule that also holds heroin and fentanyl. Salvia divinorum was added to Schedule IV by an order published in August 2015, the mescaline entry excludes peyote, and ibogaine is not listed at all. Schedule placement affects penalties and the conditions for research, so a drug’s legal category can matter more to a trial than its mechanism. HSCI 180 Lessons 11 and 12 explain how schedules were built.

National surveys use a third system, built around how respondents describe what they took. Health Canada’s Canadian Alcohol and Drugs Survey of 2019 defined hallucinogens as drugs such as LSD, PCP and psilocybin, and asked about salvia as a separate drug (Health Canada, 2021). The Canadian Substance Use Survey of 2025 asks separately about psychedelics, a category that includes salvia, and about dissociatives such as ketamine and PCP (Health Canada, 2026b). PCP is pharmacologically unlike LSD, yet the 2019 survey counted the two together, and the salvinorin A in salvia is pharmacologically unlike psilocybin, yet the 2025 survey counts those two together. Section 3 shows why these choices matter when survey estimates are compared across years.

Try it 1.1: Three ways of sorting one drug

Take ketamine and salvinorin A in turn. For each, write down its pharmacological group from Table 1.1, its CDSA schedule, and the category in which the 2019 and 2025 Canadian surveys would have counted it. Then identify one practical consequence of each kind of sorting: for a clinician choosing a monitoring plan, for a researcher applying to run a trial, and for an epidemiologist comparing survey years.

Suggested answer for Try it 1.1v

Ketamine is a dissociative (NMDA receptor inhibition), sits in CDSA Schedule I, and is counted among dissociatives in the 2025 survey. Salvinorin A is an atypical agent (kappa-opioid agonism), Salvia divinorum is in Schedule IV, and salvia was asked about separately from hallucinogens in the 2019 survey and counted among psychedelics in the 2025 survey. Mechanism guides a clinician’s monitoring plan, the schedule determines the licences a trial needs, and the survey category determines whether a change between years reflects behaviour or a change in which drugs were counted.

Part 2.1 has shown that a single drug can belong to three categories at once. Part 3.1 turns from the drugs to the treatment, and asks what turns the administration of one of these substances into a psychedelic-assisted therapy.

3.1 What Makes a Therapy Psychedelic-Assisted

Psychedelic-assisted therapy (PAT) is a structured psychotherapeutic process in which a person receives one or a few supervised doses of a psychedelic within a course of screening, preparation and integration. The therapy and the therapeutic relationship are part of the treatment, and this course treats them as such. The terms psilocybin-assisted therapy, MDMA-assisted therapy and ketamine-assisted psychotherapy name the same model with a particular drug.

3.1.1 A Process with Phases

The clearest way to see the model is to look at a published protocol. In the phase 3 trial of MDMA-assisted therapy for post-traumatic stress disorder reported by Mitchell and colleagues (2021), participants first completed screening and tapered off their psychiatric medications under supervision. They then attended three preparatory sessions, three eight-hour experimental sessions spaced about four weeks apart, and nine 90-minute integration sessions, all within about 18 weeks. The first integration session took place on the morning after each experimental session. Participants randomized to placebo received the same therapy with an inactive pill, so the trial compared MDMA plus therapy with the same therapy given with placebo.

Other trials weight the phases differently. Kelmendi and colleagues (2022) observe that one or two trained facilitators are usually present during dosing, that depression trials provide support mainly during dosing with a few integration sessions, and that trials for substance use disorders embed dosing in a multi-week course of psychotherapy. Lesson 7 examines these models, including group programs in British Columbia.

3.1.2 How This Differs from a Daily Medication

A daily medication is taken on a fixed schedule, usually at home and often for months. A trial reported by Carhart-Harris and colleagues (2021) makes the contrast concrete. Fifty-nine adults with moderate to severe major depressive disorder received either two 25 mg doses of psilocybin three weeks apart plus six weeks of daily placebo capsules, or two 1 mg doses of psilocybin plus six weeks of daily escitalopram, a selective serotonin reuptake inhibitor. Every participant received psychological support. One arm therefore took its active drug on two days, and the other took its active drug on about 42 days. In a phase 2 trial for treatment-resistant depression, Goodwin and colleagues (2022) gave a single dose of a synthetic psilocybin formulation (25 mg, 10 mg or 1 mg) with psychological support. Figure 1.2 sets these schedules side by side.

Daily escitalopram arm, 6 weeks 42 daily doses Psilocybin arm of the same trial, 6 weeks Dose 1 (25 mg)Dose 2, week 32 dosing days MDMA-assisted therapy protocol, about 18 weeks Preparation (3) Experimental session, 8 hours (3) Integration, 90 minutes (9) Spacing is schematic. Sources: Carhart-Harris et al. (2021); Mitchell et al. (2021).
Figure 1.2. Dosing schedules in two published trials: the escitalopram and psilocybin arms of Carhart-Harris and colleagues (2021), in which all participants also received psychological support, and the MDMA-assisted therapy protocol of Mitchell and colleagues (2021).

The difference in schedule brings other differences with it. Drug sessions take place in a clinic with trained staff present for many hours, and the intense acute experience is worked with in preparation and integration, so supervision and psychological work are part of the treatment. The risks are concentrated in a few days, so screening and monitoring carry much of the safety burden (Lesson 6). Any lasting benefit must persist long after the drug has left the body, which is why Lessons 8 to 10 attend closely to the length of follow-up.

Esketamine shows that the boundary between the two models is not always sharp. The United States Food and Drug Administration (FDA) approved the esketamine nasal spray Spravato on 5 March 2019 for adults with treatment-resistant depression, in combination with an oral antidepressant, under a restricted distribution program: patients take the spray under the supervision of a health care provider in a certified office or clinic and cannot take it home (FDA, 2019). Health Canada first authorized it in May 2020 for adults who had not responded to at least two antidepressants, also in combination with an antidepressant (Janssen Inc., 2021). The drug is given repeatedly under supervision without built-in psychotherapy. The three tabs below summarize the three arrangements.

The person takes a fixed dose every day, usually at home, for weeks or months, and any psychotherapy is a separate treatment. The daily escitalopram arm follows this model (Carhart-Harris et al., 2021).

The person receives one to three doses, each in a long supervised session, within a course of screening, preparation and integration, and the therapeutic relationship is part of the treatment. The MDMA protocol in Figure 1.2 follows this model (Mitchell et al., 2021).

The person takes an approved drug repeatedly under supervision in a certified clinic, with a daily oral antidepressant, and psychotherapy is not part of the approved product (FDA, 2019). Ketamine-assisted psychotherapy, which adds structured therapy, is discussed in Lesson 8.

4.1 Where Psychedelic-Assisted Therapy Is Lawful in Canada

The same drug can be part of a lawful treatment or of an offence, depending on the route by which it is obtained and given. The box below summarizes Health Canada’s description, and Lesson 11 examines each route.

Lawful routes for psychedelic-assisted therapy in Canada (as of October 2026)

Health Canada’s public page on psilocybin, last modified on 8 October 2025, states that the production, sale and possession of magic mushrooms are illegal in Canada. It names three pathways for authorized access: clinical trials, the Special Access Program, and individual exemptions under subsection 56(1) of the CDSA. The same page states that no therapeutic product containing psilocybin had been approved in Canada or elsewhere (Health Canada, 2025).

Since 1 October 2026, the Special Access Program route for restricted drugs such as psilocybin and MDMA has been governed by the Controlled Substances Regulations (SOR/2025-242), which allow a practitioner named in a Special Access Program letter of authorization to administer or provide the drug. These regulations replaced Part J of the Food and Drug Regulations and other older regulations. They also absorbed the subsection 56(1) class exemption that Health Canada had issued for psilocybin and MDMA after amendments in January 2022 restored access to restricted drugs through the program (Canada Gazette, 2025). Lesson 11 describes this history.

Because psilocybin, MDMA and LSD are scheduled substances, section 4 of the CDSA makes it an offence to possess them except as authorized under the regulations, and section 21 of the Criminal Code makes anyone who aids or abets an offence a party to it. A regulated professional who gives preparation or integration support for unauthorized use may therefore be at legal risk. Lessons 7 and 11 explain this position as a matter of law; it is not legal advice for any individual situation.

Each of these routes authorizes a specific person to receive a specific drug under specific conditions, and psychedelic-assisted therapy supplies the screening, supervision and integration that those conditions assume. Case 1.1 shows the same molecule without that structure.

Case 1.1: One molecule, two settings

In the phase 2 trial of Goodwin and colleagues (2022), adults with treatment-resistant depression were screened, received a single dose of a synthetic psilocybin formulation with psychological support, and were followed for 12 weeks with standardized ratings. In May 2024, Matsukubo and colleagues (2025) identified 57 unlicensed psilocybin dispensaries in Canada. Almost all of the stores they examined sold dried mushrooms and microdosing capsules, most sold psilocybin chocolate and gummies, and 86.4 percent of the dispensary websites claimed mental health benefits, such as relief of anxiety. The authors noted that the websites very rarely mentioned that the benefits reported in trials came from psychedelic-assisted therapy.

The molecule is the same in both settings, while the dose, screening, support, follow-up and evidence differ. Section 3 returns to these storefronts, and Section 4 asks how to judge their claims.

Summary

This section defined the classic psychedelics by their shared action at the 5-HT2A receptor and placed MDMA, ketamine, ibogaine and salvinorin A in separate groups by primary mechanism. Canadian law and Canadian surveys sort the same drugs in other ways, so a reader must ask which system a source uses. Psychedelic-assisted therapy is a phased process of screening, preparation, one or a few supervised dosing sessions and integration, distinct from daily medication and from supervised esketamine, and in Canada, as of October 2026, it can take place lawfully only through the routes described in Part 4.1.

Section 2 turns to the experiences these drugs produce. It asks how researchers measure perceptual, emotional, cognitive and self-related changes, how user-reported sources describe them, and what each kind of source can and cannot establish.

Key Takeaways

  • 1.1 In its narrow, pharmacological sense, a psychedelic is a classic serotonergic psychedelic: a drug that acts as an agonist or partial agonist at serotonin 2A (5-HT2A) receptors. Psilocybin, LSD, DMT and mescaline come from three chemical families (tryptamines, ergolines and phenethylamines), yet they form one class because they act through the same receptor. Words such as hallucinogen, entheogen and entactogen each emphasize a different part of the experience, so a careful reader checks which meaning an author intends.
  • 1.2 MDMA, ketamine, ibogaine and salvinorin A produce related experiences through different primary mechanisms. MDMA, the entactogen, is carried into neurons by the serotonin transporter and releases serotonin; ketamine, the dissociative, inhibits NMDA glutamate receptors; salvinorin A is a selective kappa-opioid agonist, and ibogaine acts at many targets. Because mechanism shapes effects, risks and drug interactions, findings about one drug cannot be transferred to the others.
  • 2.1 The Controlled Drugs and Substances Act does not follow pharmacology: as of October 2026, the classic psychedelics sit in Schedule III, MDMA and ketamine in Schedule I, salvia in Schedule IV, and ibogaine outside the Act. National surveys use a third system, so the 2019 survey counted PCP with LSD and psilocybin, and the 2025 survey counts salvia with psychedelics. A reader must ask which system a source uses, because each kind of sorting matters to a different decision.
  • 3.1 Psychedelic-assisted therapy places one or a few supervised dosing sessions inside a course of screening, preparation and integration, as in the MDMA protocol of Mitchell and colleagues (2021). In the trial of Carhart-Harris and colleagues (2021), the psilocybin arm took its active drug on two days and the escitalopram arm on about 42 days. Supervised esketamine sits between the two models: it is given repeatedly in a certified clinic without built-in psychotherapy.
  • 4.1 As of October 2026, Health Canada names three authorized routes for psychedelic-assisted therapy with a controlled substance: clinical trials, the Special Access Program and subsection 56(1) exemptions. Since 1 October 2026 the Special Access Program route has been governed by the Controlled Substances Regulations. Outside these routes, possession is an offence, and the same molecule sold in a storefront comes without the screening, support and follow-up that trials provide.

Reflection

A hypothetical news article describes psilocybin, MDMA, ketamine and ibogaine as “psychedelics that all work the same way” and suggests that a person could “take them at home like an antidepressant.” Use these facts to write a correction of 150 to 250 words. Psilocybin is converted to psilocin, which activates serotonin 2A (5-HT2A) receptors. MDMA is carried into neurons by the serotonin transporter, which then releases stored serotonin. Ketamine inhibits NMDA glutamate receptors. Ibogaine acts at many targets, including monoamine transporters and NMDA and nicotinic receptors, and its metabolite noribogaine activates kappa-opioid receptors. In one trial, one group received two 25 mg doses of psilocybin three weeks apart with psychological support, while the other took escitalopram every day for six weeks (Carhart-Harris et al., 2021). In an MDMA trial, participants attended three preparatory sessions, three eight-hour experimental sessions and nine integration sessions over about 18 weeks (Mitchell et al., 2021). As of October 2026, psilocybin and MDMA are scheduled under Canada’s Controlled Drugs and Substances Act, and Health Canada names clinical trials, the Special Access Program and subsection 56(1) exemptions as the authorized routes. Explain (a) why grouping the four drugs as working “the same way” is misleading, and (b) how psychedelic-assisted therapy differs from taking a daily medication, including where it can lawfully take place in Canada.

Model answer

The four drugs produce some overlapping experiences, yet they act through different targets. Psilocybin works through psilocin, which activates serotonin 2A receptors, the defining action of the classic psychedelics. MDMA is an entactogen: the serotonin transporter carries it into neurons, and stored serotonin is released. Ketamine is a dissociative that inhibits NMDA glutamate receptors, and ibogaine acts at many targets at once, with a metabolite that activates kappa-opioid receptors. Because mechanism shapes effects, risks and drug interactions, a claim about one of these drugs cannot be transferred to the others.

The comparison with an antidepressant is also misleading. In the trial by Carhart-Harris and colleagues, the escitalopram group took a pill on about 42 days, while the psilocybin group took the active drug on two days, each time with psychological support. The MDMA protocol of Mitchell and colleagues placed three supervised eight-hour sessions inside a course of three preparatory and nine integration sessions. Supervision, preparation and integration are part of the treatment, which is why psychedelic-assisted therapy is delivered in clinics with trained staff. As of October 2026, psilocybin and MDMA can lawfully be given for therapy in Canada only through a clinical trial, the Special Access Program or a subsection 56(1) exemption.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: What feature defines the classic psychedelics as a pharmacological class?

Nichols (2016) reports a consensus that classic psychedelics are agonists or partial agonists at 5-HT2A receptors, and Kelmendi and colleagues (2022) describe these receptors as essential for their subjective effects. A shared structure is tempting, but the class spans three chemical families: tryptamines such as psilocybin, ergolines such as LSD and phenethylamines such as mescaline. Schedule III is a legal category, and dissociation describes ketamine.

Question 2: Which statement about MDMA is consistent with Nichols (2022)?

Nichols (2022) describes MDMA’s mechanism as transport into neurons by the serotonin reuptake carrier followed by release of stored serotonin, and he named the class entactogens. MDMA is a phenethylamine, but Kelmendi and colleagues (2022) note that it binds weakly or not at all to serotonin receptors, so its structure does not make it a classic psychedelic. NMDA blockade describes ketamine, and kappa-opioid agonism describes salvinorin A.

Question 3: In the trial reported by Carhart-Harris and colleagues (2021), how did dosing in the psilocybin arm differ from dosing in the escitalopram arm?

The psilocybin arm received two 25 mg doses three weeks apart plus daily placebo, and the escitalopram arm received two 1 mg doses of psilocybin plus six weeks of daily escitalopram. All participants received psychological support, so option c is wrong, and the contrast between two dosing days and about 42 daily doses is the point of Figure 1.2.

Question 4: According to Health Canada’s psilocybin page (modified in October 2025), which of the following is an authorized route of access to psilocybin?

Health Canada names three pathways: clinical trials, the Special Access Program and individual subsection 56(1) exemptions. A municipal licence does not authorize sale under the Controlled Drugs and Substances Act, as Health Canada’s March 2024 letter to Vancouver stated. The Prescription Drug List applies to ibogaine, which is outside the Act, and no exemption is automatic.
Section 2 of 5

Subjective Effects: Research Scales, User-Reported Sources and What Each Can Establish

⏱ Estimated reading time: 40 minutes
Section 2 of 5

Subjective Effects

Research scales, user-reported sources and what each can establish.

Four domains

What changes during a psychedelic experience

Perceptual

Elementary and complex imagery, synesthesia, changed meaning of percepts.

Emotional

Blissful states, and anxiety or dread.

Cognitive

Insightfulness, impaired control of thought, altered time.

Self-related

Unity, disembodiment, ego dissolution.

Domains follow a review (Preller and Vollenweider, 2018); drug differences come from pooled laboratory data (Studerus et al., 2010).

Research scales

The 5D-ASC

94items on 0 to 100 visual analogue scales
5dimensions, from oceanic boundlessness to vigilance reduction
11lower-order scales derived from pooled laboratory sessions (Studerus et al., 2010)

A 2024 review of 93 trials of classic psychedelics found the 5D-ASC was the rating scale used most often (Hovmand et al., 2024).

Research scales

The MEQ30 and the complete mystical experience

Mystical
Positive mood
Transcendence of time and space
Ineffability
Percentage of maximum for one factor
\[ P = \frac{\text{mean item score}}{5} \times 100 \]

“Complete” when every factor is at least 60 percent; in the validation study, about half of 184 psilocybin sessions qualified (Barrett et al., 2015).

Research scales

Ego dissolution and challenging experiences

Ego Dissolution Inventory

Eight items. In one online survey, scores rose with dose for psychedelics, but not for cocaine or alcohol (Nour et al., 2016).

Challenging Experience Questionnaire

Twenty-six items in seven factors, from grief and fear to paranoia (Barrett et al., 2016).

Scales make experiences comparable. Their items reflect researchers’ choices, ratings are retrospective, and development samples are often small and self-selected (Herrmann et al., 2023).

User-reported sources

PsychonautWiki, Erowid and TripSit

PsychonautWiki

A Subjective Effect Index built mainly from contributors’ experiences and online reports.

Erowid

More than 45,000 first-hand experience reports as of October 2026.

TripSit

Volunteer harm reduction chat and factsheets.

They document vocabulary and experiences and can suggest hypotheses (Ballentine et al., 2022). They cannot show frequency, verify the drug, or establish efficacy or safety.

Carry forward

Three kinds of source

  • Research scales: comparable and controlled, with researcher-chosen items.
  • Qualitative studies: meaning in people’s own words, from small samples (Breeksema et al., 2020).
  • User-reported sources: broad vocabulary, no verification.
  • Next: who uses psychedelics, and how.

Introduction

Psychedelics are defined by what they do to experience, so any account of them depends on how experience is described. Researchers rate experiences on standardized questionnaires, interview people about what happened to them, and analyze large collections of written reports. People who use psychedelics, for their part, have built their own vocabularies and reference works, and clients bring that vocabulary into clinics. Each kind of source answers some questions well and others poorly.

Part 5.1 describes four domains of change that recur across sources. Part 5.2 explains four research scales, and Part 5.3 works through the scoring rule of one of them with a calculator. Part 6.1 considers what research scales can and cannot establish, Part 6.2 describes three user-reported or user-facing resources and the research that has drawn on them, and Part 6.3 compares the three kinds of source. Lesson 5 later asks how the experience relates to therapeutic outcomes and to blinding; this section concerns description and measurement.

Learning Objectives

  • 5.1 Describe the perceptual, emotional, cognitive and self-related changes that psychedelics produce, using the vocabulary of research scales.
  • 5.2 Explain the structure and scoring of the 5D-ASC, the MEQ30, the Ego Dissolution Inventory and the Challenging Experience Questionnaire.
  • 5.3 Calculate whether a set of MEQ30 factor scores meets the research criterion for a “complete mystical experience”, and explain the limits of that threshold.
  • 6.1 Explain what research scales can and cannot establish about psychedelic experiences, given how they were built and validated.
  • 6.2 Describe PsychonautWiki’s Subjective Effect Index, Erowid’s Experience Vaults and TripSit as user-reported or user-facing sources, and state what such sources can and cannot establish.
  • 6.3 Compare what research scales, qualitative studies and user-reported sources can and cannot establish about psychedelic experiences.

5.1 Four Domains of Subjective Change

Preller and Vollenweider (2018) describe the state produced by classic psychedelics as an altered state of consciousness marked by profound changes in sensory perception, mood, thought (including the perception of reality) and the sense of self. This course groups these changes into four domains: perceptual, emotional, cognitive and self-related.

The four tabs below describe each domain, using the names of the lower-order scales that Studerus, Gamma and Vollenweider (2010) derived from a standard research questionnaire, and the corresponding headings in PsychonautWiki’s user-contributed Subjective Effect Index (PsychonautWiki, 2026).

Perceptual changes include elementary imagery (patterns, colours and lights, often with the eyes closed), complex imagery (scenes and figures), audio-visual synesthesia (sounds that change what is seen) and a changed meaning of percepts, in which ordinary objects seem significant (Studerus et al., 2010). Kelmendi and colleagues (2022) describe perceptual alterations akin to visual hallucinations, illusions and synesthesia. PsychonautWiki lists visual effects under the subheadings amplifications, suppressions, distortions, geometry and hallucinatory states, with further headings for auditory, tactile and multisensory effects.

Emotional changes range from a blissful state of deep positive mood to anxiety (Studerus et al., 2010). Kelmendi and colleagues (2022) note that psilocybin can induce anxiety and distressing effects, including a dread of ego dissolution. Research and clinical writing calls an episode of intense fear, grief or distress a challenging experience; people who use psychedelics often call it a “bad trip”. Lesson 5 examines how often such experiences occur and how people make meaning of them.

Cognitive changes include insightfulness, a sense of new understanding about oneself or one’s life, and impaired control and cognition, such as difficulty directing thought (Studerus et al., 2010). Changes in the perception of time are also common (Preller & Vollenweider, 2018). PsychonautWiki divides cognitive effects into enhancements, depressions, intensifications, suppressions, novel, psychological and transpersonal effects, and lists thought loops and time distortion among the novel effects.

Self-related changes include an experience of unity with one’s surroundings, disembodiment and spiritual experience (Studerus et al., 2010). Ego dissolution, a temporary loss of the usual sense of being a separate self, is described by Nour and colleagues (2016) as a key feature of the psychedelic experience. Kelmendi and colleagues (2022) report that psilocybin increases feelings of unity and of transcendence of time and space. PsychonautWiki lists ego dissolution and unity under “transpersonal”, a subheading of its cognitive effects.

Two further points apply across the domains. The first is that the state changes over time: Preller and Vollenweider (2018) describe people progressing through stages during a session, along a continuum from perceptual change towards hallucination with increasing arousal and ego dissolution. The second is that profiles differ between drugs. In data pooled by Studerus and colleagues (2010), sessions with psilocybin scored much higher than sessions with MDMA on elementary imagery, and sessions with ketamine scored higher than MDMA sessions on disembodiment and lower on blissful state. These differences fit the separate groups in Section 1: the drugs share a family resemblance in experience while differing in mechanism.

The domains give a vocabulary, but a vocabulary does not measure anything. Part 5.2 explains how researchers turn these descriptions into numbers that can be compared across people, doses and drugs.

5.2 Measuring the Experience with Research Scales

A research scale is a fixed set of questionnaire items, each rated on a defined response format, that has been tested for reliability and validity in a stated population. Scales make experiences comparable, and their limits come from the same source as their strengths: the researchers decide in advance what will be asked.

5.2.1 The 5D-ASC

In a 2024 review of 93 trials of classic psychedelics, Hovmand and colleagues (2024) found that the 5D-ASC described below was the rating scale used most often. It belongs to a family of questionnaires for altered states that began with Dittrich’s APZ, which had 158 yes-or-no items; its revision, the OAV, has 66 items rated on visual analogue scales, horizontal lines on which the respondent marks a point between “no, not more than usual” and “yes, very much more than usual”, scored from 0 to 100 (Studerus et al., 2010). The OAV measures three primary dimensions: oceanic boundlessness, a positively experienced loss of boundaries similar to mystical experience; dread of ego dissolution, a negatively experienced loss of self with cognitive disturbance and loss of control; and visionary restructuralization, which covers imagery and changed meaning. An extended version published in 1999, the five-dimensional altered states of consciousness questionnaire (5D-ASC), adds 16 items on auditory alterations and 12 on vigilance reduction, for 94 items in all.

Studerus and colleagues (2010) tested the structure of the OAV using 591 drug sessions pooled from 43 experimental studies with healthy volunteers in Zurich between 1992 and 2008: 327 psilocybin sessions, 162 ketamine sessions and 102 MDMA sessions. The original three dimensions turned out to combine several distinct experiences, so the authors derived 11 more specific lower-order scales with good psychometric properties that differentiated well among the three drugs. Figure 1.3 shows how the scales relate to the original dimensions.

Oceanicboundlessness Dread of egodissolution Visionaryrestructuralization Auditoryalterations Vigilancereduction Experience of unity Spiritual experience Blissful state Insightfulness Disembodiment Impaired controland cognition Anxiety Complex imagery Elementary imagery Audio-visual synesthesia Changed meaningof percepts Added in the5D-ASC (1999) Three primary dimensions (solid) with the 11 lower-order scales derived from the 66 OAV items; two added dimensions (dashed) complete the 94-item 5D-ASC.
Figure 1.3. The structure of the 5D-ASC. Each of the 11 lower-order scales is placed under the original dimension with which it correlated most strongly in the pooled data of Studerus and colleagues (2010, Table 3); the lower-order scales were derived from the OAV items only.

5.2.2 The Mystical Experience Questionnaire (MEQ30)

The Mystical Experience Questionnaire grew from a philosophical account of mysticism. Following an account of mysticism by W. T. Stace (1960), as described by Barrett and colleagues (2015), it treats a mystical experience as combining unity, a felt sense of sacredness, a sense of encountering truth (noetic quality), deeply felt positive mood, transcendence of time and space, and difficulty describing the experience in words (ineffability). The earlier 43-item version had seven subscales; the revised 30-item version, the MEQ30, reduces them to four factors: mystical (unity, noetic quality and sacredness), positive mood, transcendence of time and space, and ineffability. Each item is rated from 0 (“none; not at all”) to 5 (“extreme”) (Barrett et al., 2015).

5.2.3 Ego Dissolution and Challenging Experiences

Two shorter or more specialized scales complete the set used in this course. Nour and colleagues (2016) developed the Ego Dissolution Inventory (EDI), an 8-item scale rated on visual analogue lines. In an internet survey of 691 people describing 1,828 drug experiences, EDI scores rose with dose for psychedelics, but not for cocaine or alcohol, which supported the claim that ego dissolution is specific to psychedelic states. Barrett and colleagues (2016) developed the Challenging Experience Questionnaire (CEQ) from an internet survey of difficult experiences with psilocybin mushrooms; its 26 items form seven factors: grief, fear, death, insanity, isolation, physical distress and paranoia. Lesson 5 uses the CEQ to examine how often challenging experiences occur. Table 1.2 summarizes the four instruments.

Table 1.2. Four research scales for psychedelic experiences, with their structure, response format and development sample.

ScaleWhat it measuresStructure and formatDevelopment or validation sample
5D-ASC (Studerus et al., 2010)Altered states of consciousness from any cause94 items on 0 to 100 visual analogue scales; 5 dimensions and 11 lower-order scales591 laboratory sessions with psilocybin, ketamine or MDMA in healthy volunteers, Zurich, 1992 to 2008
MEQ30 (Barrett et al., 2015)Mystical-type experience30 items rated 0 to 5; 4 factors; “complete” when every factor is at least 60 percent of the maximum184 participants given psilocybin in five laboratory studies at Johns Hopkins University
EDI (Nour et al., 2016)Ego dissolution8 items on visual analogue scales; one factorInternet survey of 691 people describing 1,828 experiences with psychedelics, cocaine or alcohol
CEQ (Barrett et al., 2016)Challenging experiences26 items; 7 factorsInternet survey of people describing a difficult experience with psilocybin mushrooms

5.3 The Complete Mystical Experience Criterion

One feature of the MEQ30 needs closer attention, because it turns a profile of scores into a single yes-or-no outcome that trials often report.

Barrett, Johnson and Griffiths (2015) validated the MEQ30 with data pooled from five laboratory studies approved by the Johns Hopkins University School of Medicine in which 184 participants received a moderate to high oral dose of psilocybin and completed the questionnaire about seven hours after taking the capsule. Scores on the mystical factor predicted participants’ later ratings of the spiritual significance of the session and of positive changes in behaviour they attributed to it. The authors also adapted a dichotomous rule from the earlier version: a session counts as a complete mystical experience when the score on every one of the four factors is at least 60 percent of the maximum possible score. Under this rule, 94 of the 184 sessions (51 percent) qualified.

Equation 1.1 gives the calculation for one factor. Because every item has a maximum of 5, the percentage of the maximum equals the mean item score divided by 5.

Percentage of the maximum score on one MEQ30 factor
P = (mean item score ÷ 5) × 100Eq 1.1
the percentage of the maximum equals the average rating across the items of that factor, divided by the highest possible rating of 5, multiplied by 100. A session meets the criterion for a complete mystical experience when this percentage is 60 or more on all four factors.

Worked example. Suppose a hypothetical participant’s mean item scores are 3.6 on the mystical factor, 3.2 on positive mood, 3.9 on transcendence of time and space and 2.8 on ineffability. The percentages are 3.6 ÷ 5 × 100 = 72, 3.2 ÷ 5 × 100 = 64, 3.9 ÷ 5 × 100 = 78 and 2.8 ÷ 5 × 100 = 56. Three factors pass the 60 percent threshold and ineffability does not, so the session does not meet the criterion, even though its average across the four factors is 67.5 percent. Use Calculator 1.1 to try other profiles, and notice that one low factor decides the classification however high the others are.

The rule is a research convention. It turns a continuous profile into a yes-or-no category, which is convenient for reporting the share of participants who had a complete experience, and it discards information, since a participant at 59 percent on one factor is classified with one at 10 percent.

6.1 What Research Scales Can and Cannot Establish

What these scales can establish follows from how they were built. Because every respondent answers the same items, scales can show how experience changes with dose, how drugs differ, and whether features of the acute experience predict later outcomes. Their limits follow from the same design. The ratings are retrospective, made hours or years after the experience. The items reflect theories chosen by researchers, such as Stace’s account of mysticism, which comes from one philosophical and religious tradition. The development samples in Table 1.2 were mostly healthy or screened volunteers in laboratories and self-selected internet respondents, who may differ from patients in trials, and a 2023 scoping review by Herrmann and colleagues (2023) noted that the samples used for such scales are often small and self-selected. Part 6.2 turns to sources in which people describe their experiences in their own words.

6.2 User-Reported Sources

Most people who use psychedelics never take part in a study, and they have built their own resources for describing what happens. Clients in psychedelic-assisted therapy often arrive having read them. The three resources below are user-contributed or user-facing; this course cites them for what people who use psychedelics report and for the harm reduction information they publish, and never as evidence that a drug is effective or safe.

PsychonautWiki and its Subjective Effect Indexv

PsychonautWiki describes its Subjective Effect Index as a collection of wiki articles intended as a comprehensive reference work on the effects of psychoactive substances, and hopes its definitions will become a universal terminology. Its articles use a formalized style that avoids metaphor, and each entry gives a name, a description of the experience and related information. The site states that its content is derived principally from the collective experiences and analyses of its contributors, from anecdotal reports collected on the internet and, whenever possible, from published scientific literature (PsychonautWiki, 2026). Its top-level headings are visual, auditory, tactile, disconnective, smell and taste, multisensory, cognitive, physical and uncomfortable physical effects. The site also publishes dosage and interaction pages written from user reports, which this course does not reproduce.

Erowid’s Experience Vaultsv

Erowid describes itself as a member-supported organization that provides reliable, non-judgemental information about psychoactive plants, chemicals and related issues (Erowid, 2017). Its Experience Vaults hold more than 45,000 first-hand reports, which Erowid states are the writings and opinions of the people who submit them; a review team screens and sorts the submissions (Erowid, n.d.).

TripSitv

TripSit describes its mission as harm reduction through education. Unpaid volunteers run live chat support and publish drug factsheets that use PsychonautWiki’s Subjective Effect Index, and the site states that it is not a replacement for medical help because its volunteers are not medical professionals (TripSit, 2016).

Researchers have begun to analyze such collections at scale. Zamberlan and colleagues (2018) applied natural language processing to reports from Erowid’s Experience Vaults and found preliminary evidence that drugs with similar receptor-binding profiles were described in more similar language. Ballentine, Friedman and Bzdok (2022) analyzed word use in 6,850 free-form testimonials about 27 drugs and linked patterns of description to the distribution of 40 neurotransmitter receptor subtypes in the brain. Both studies used user reports to generate hypotheses about mechanism that laboratory studies of one drug at a time could not easily produce. These are early, exploratory studies: Zamberlan and colleagues described their evidence as preliminary, and both sets of findings remain hypotheses for laboratory research to test.

The box below sets out what this kind of source can support. Its central point is that a report describes an experience as the person understood it, without an independent check of what was taken or how often such experiences occur.

What user-reported sources can and cannot establish

User-reported sources can establish the vocabulary that people who use psychedelics use, the range of experiences they describe, including rare or unusual ones, the meanings they give to those experiences, and the harm reduction information that communities circulate. They can also generate hypotheses for research, as the studies of Erowid reports show.

They cannot establish how often an effect occurs, because there is no denominator: no one knows how many people had a similar experience and did not write about it. They cannot confirm what substance or dose was taken; in a citizen-science study of microdosing, the investigators listed the lack of verification of the nature, purity and dose of the substances as a key limitation (Szigeti et al., 2021), and Health Canada (2025) warns that illegally produced drugs are not tested. They cannot show that a drug caused an outcome, and they are never evidence that a drug is effective or safe.

User reports, then, are rich in description and weak in verification, which is nearly the reverse of research scales. Part 6.3 places them beside qualitative research and the scales to compare all three.

6.3 Comparing the Three Kinds of Source

A third kind of source lies between the scale and the online report. Qualitative studies interview participants in trials or treatment programs and analyze what they say with defined methods. Breeksema and colleagues (2020) synthesized 15 such studies covering 178 patients treated with psilocybin, LSD, ibogaine, ayahuasca, ketamine or MDMA for conditions including depression, anxiety, eating disorders, post-traumatic stress disorder and substance use disorders. Despite the different drugs and settings, patients described comparable processes, including insight, altered self-perception, increased connectedness, transcendental experiences and an expanded range of emotion.

Table 1.3 compares the three kinds of source on who reports, how the experience is captured, what is verified, and which claims each can support.

Table 1.3. Research scales, qualitative studies and user-reported sources compared.

FeatureResearch scalesQualitative studiesUser-reported sources
Who reportsStudy participants, often healthy volunteers or screened patientsParticipants in trials or programs, usually small groupsSelf-selected writers and contributors
How experience is capturedFixed items with numeric ratingsInterviews in the person’s own words, analyzed systematicallyFree-form reports, edited summaries and wiki articles
Substance and dose verifiedYes, in laboratory and trial studiesYes, when drawn from trialsNo
Strongest useComparing doses, drugs and people; predicting later outcomesUnderstanding meaning and therapeutic processesVocabulary, breadth of experiences, hypotheses, harm reduction information
Main limitsResearchers choose the items; ratings are retrospectiveSmall, selected samples; findings depend on the analystsNo denominator, no verification, no evidence of efficacy or safety
Try it 1.2: Match the claim to the source

For each of these hypothetical statements, decide which kind of source in Table 1.3 could best support it, and why. (a) “People who use psychedelics describe a visual effect they call tracers.” (b) “Higher doses of psilocybin produce more ego dissolution than lower doses.” (c) “Patients in a trial described feeling more connected to others after treatment.” (d) “Most people who microdose experience improved focus.”

Suggested answers for Try it 1.2v

(a) A user-reported source is the right evidence for what people who use psychedelics call an effect, and PsychonautWiki lists tracers among visual distortions. (b) A research scale, such as the EDI, given at controlled doses can test a dose-response claim; Nour and colleagues (2016) found that EDI scores rose with reported dose for psychedelics. (c) A qualitative study of trial participants can document this, as in the synthesis by Breeksema and colleagues (2020). (d) None of the sources in this section can support a claim about most people, because it requires a representative sample and a measured outcome; Section 3 shows how surveys and trials address such claims, and Section 4 shows how to judge them.

Summary

This section described four domains of subjective change (perceptual, emotional, cognitive and self-related) and showed that their profiles differ between drugs and over the course of a session. It explained the 5D-ASC, the MEQ30, the EDI and the CEQ, including the MEQ30 rule for a complete mystical experience, and noted that scales are comparable across people because researchers fix the items in advance. It described PsychonautWiki, Erowid and TripSit as user-reported or user-facing sources that are rich in vocabulary and unverified, and compared them with research scales and qualitative studies.

Section 3 moves from the experience to the people who have it. It asks how many people in Canada and the United States use psychedelics, in what forms and settings, and what surveys and studies of storefronts, microdosing and retreats can tell us about them.

Key Takeaways

  • 5.1 The changes that psychedelics produce fall into four domains: perceptual (elementary and complex imagery, synesthesia, changed meaning of percepts), emotional (from blissful states to anxiety), cognitive (insightfulness, impaired control, altered time) and self-related (unity, disembodiment, ego dissolution). The state changes over the course of a session, and profiles differ between drugs, so psilocybin, MDMA and ketamine share a family resemblance in experience while differing in mechanism.
  • 5.2 The 94-item 5D-ASC measures altered states from any cause on 0 to 100 visual analogue scales, with five dimensions and 11 lower-order scales. The MEQ30 rates 30 items from 0 to 5 on four factors drawn from Stace’s account of mysticism. The 8-item Ego Dissolution Inventory and the 26-item Challenging Experience Questionnaire, with seven factors, complete the set used in this course.
  • 5.3 A session counts as a complete mystical experience when every one of the four MEQ30 factors reaches at least 60 percent of its maximum, which equals a mean item score of 3.0 or more on each factor. One low factor decides the classification however high the others are, and the rule discards information by treating a score of 59 percent like a score of 10 percent. It is a research convention for reporting, not a natural boundary in experience.
  • 6.1 Because every respondent answers the same items, research scales can show how experience changes with dose, how drugs differ, and whether the acute experience predicts later outcomes. Their limits follow from the same design: the ratings are retrospective, the items reflect theories chosen by researchers, and the development samples were mostly healthy or screened volunteers or self-selected internet respondents.
  • 6.2 PsychonautWiki, Erowid and TripSit are user-contributed or user-facing resources that document the vocabulary, range of experiences and harm reduction information that circulate among people who use psychedelics, and studies of Erowid reports have used them to generate hypotheses about mechanism. They cannot establish how often an effect occurs, confirm what substance or dose was taken, or show cause, and they are never evidence that a drug is effective or safe.
  • 6.3 Research scales are strong for comparison, qualitative studies for understanding meaning and therapeutic processes, and user-reported sources for vocabulary, breadth and hypotheses. Only scales and qualitative studies drawn from trials verify substance and dose, and none of the three can support a claim about how most people respond without a representative sample and a measured outcome.

Reflection

A friend shows you two accounts of “ego dissolution”. The first is a PsychonautWiki article; the site states that its Subjective Effect Index is derived mainly from contributors’ experiences and analyses, anecdotal reports collected online and, where possible, published research. The second is a laboratory study in which 184 participants given psilocybin completed the 30-item Mystical Experience Questionnaire (MEQ30; four factors, each item rated from 0 to 5) about seven hours after dosing, and in which 94 participants met the criterion for a complete mystical experience: at least 60 percent of the maximum score on every one of the four factors (Barrett et al., 2015). In 150 to 250 words, explain what each source can and cannot establish about ego dissolution or mystical-type experience, and describe one study that would use both kinds of source together. In your answer, show whether a hypothetical participant with mean factor scores of 3.4 (mystical), 3.1 (positive mood), 3.6 (transcendence of time and space) and 2.9 (ineffability) meets the MEQ30 criterion.

Model answer

The PsychonautWiki article shows how people who use psychedelics describe ego dissolution and what vocabulary they share. Because it is assembled from self-selected reports, it cannot tell us how often ego dissolution occurs, which substance or dose produced it, or whether it is harmful or helpful. The laboratory study gives a standardized measure in people whose drug and dose were known, so it can compare participants and doses and relate scores to later outcomes. Its limits are that the items were chosen by researchers following one philosophical account of mysticism, that ratings are retrospective, and that its 184 participants were screened volunteers.

For the hypothetical participant, the percentages of the maximum are 3.4 ÷ 5 × 100 = 68, 3.1 ÷ 5 × 100 = 62, 3.6 ÷ 5 × 100 = 72 and 2.9 ÷ 5 × 100 = 58. Ineffability falls below 60 percent, so the profile does not meet the criterion, although its average is 65 percent.

A combined study could first analyze a large set of user reports to identify how people describe ego dissolution, then write candidate questionnaire items in that vocabulary and test them in a trial alongside the MEQ30 and the Ego Dissolution Inventory, checking whether the new items add information that the existing scales miss.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: Under the rule adapted by Barrett and colleagues (2015), when does an MEQ30 profile count as a complete mystical experience?

The rule requires a score of at least 60 percent of the maximum on every one of the four factors (mystical, positive mood, transcendence of time and space, and ineffability). An average can be high while one factor is low, which is why option a is the most tempting error; the worked example in Section 2 averages 67.5 percent and still does not qualify.

Question 2: A hypothetical participant’s mean MEQ30 item scores are 4.0 (mystical), 3.5 (positive mood), 3.0 (transcendence of time and space) and 2.9 (ineffability). How is this profile classified?

Dividing each mean by 5 and multiplying by 100 gives 80, 70, 60 and 58 percent. Transcendence of time and space meets the threshold exactly, but ineffability falls below it, so the profile is not complete. The average of 67 percent is irrelevant under the rule, and there is no 75 percent threshold.

Question 3: Which conclusion can a user-reported source such as PsychonautWiki’s Subjective Effect Index support?

User-reported sources document vocabulary and the range of experiences people describe. They cannot give frequencies because there is no denominator, they cannot verify substance or dose, and they cannot show cause or establish safety or efficacy (Section 2, 6.2 User-Reported Sources). Option b is the most dangerous misreading, because the course never treats such sources as evidence of safety.

Question 4: In the data pooled by Studerus and colleagues (2010), how did ketamine sessions differ from MDMA sessions?

With MDMA as the reference group, ketamine sessions scored higher on disembodiment and lower on blissful state. Option a reverses both directions. The largest difference on elementary imagery was for psilocybin sessions, and the authors reported that the new scales differentiated well among the three drugs.
Section 3 of 5

Who Uses Psychedelics, and How: Surveys, Microdosing, Retreats and Storefronts

⏱ Estimated reading time: 40 minutes
Section 3 of 5

Patterns of Use

Surveys, microdosing, retreats and storefronts.

Measuring use

The Canadian Substance Use Survey

36,061respondents aged 15+ in the 2025 cycle
1.2 million+randomly generated telephone numbers called to recruit them
Every 2 yearsconducted by Health Canada, as of 2026

Results cannot be adjusted for non-response, so margins of error may look smaller than they are (Health Canada, 2026a).

What the survey shows

Psilocybin dominates, and the questions changed

7%past-year use of any psychedelic in 2025, about 2.6 million people
16% → 27%lifetime use, 2023 to 2025, after the questions became more specific

Of people who used any illegal or other substance of concern in 2025, 43 percent used only psilocybin.

Who uses psychedelics

Concentrated in some groups

By age

About 13 percent at ages 18 to 34; about 1 percent at 65 or older.

By mental health

13.1 percent with fair or poor self-rated mental health; 6.0 percent among others.

A cross-sectional survey shows association. It cannot show which way the relationship runs.

Beyond Canada, and microdosing

United States trends and the microdosing evidence

  • United States adults aged 19 to 30: past-year hallucinogen use rose from 3 percent in 2012 to 9 percent in 2023 (NIDA, 2023; University of Michigan, 2024).
  • About 1 in 15 young adults reported microdosing in 2022 to 2023 (Keyes et al., 2026).
  • In one self-blinding study, microdose and placebo groups improved to a similar extent (Szigeti et al., 2021).
  • A 2026 meta-analysis found no clear benefit over placebo in trials with healthy adults (Meshkat et al., 2026).
Retreats and storefronts

Use outside clinics

Retreats and ceremonies

In one large online survey of people who used ayahuasca, physical adverse effects were more likely without supervision (Bouso et al., 2022).

Unlicensed storefronts

57 stores in May 2024 and 75 by July 2025 (Matsukubo et al., 2025; 2026). Health Canada wrote on 15 March 2024 that they are not authorized.

Carry forward

From patterns of use to weighing claims

  • About 7 percent of people aged 15+ in Canada used a psychedelic in 2025, mostly psilocybin.
  • Questionnaire changes make the apparent rise hard to interpret.
  • Evidence on microdosing and retreats here comes from surveys and small placebo-controlled designs; a 2026 review found the trial evidence on microdosing inconclusive (Meshkat et al., 2026).
  • Next: how to judge the claims these settings generate.

Introduction

Most psychedelic use takes place outside clinics and trials. In 2025, Health Canada estimated that about 2.6 million people in Canada aged 15 or older had used a psychedelic in the past 12 months (Health Canada, 2026a), while the trials described in later lessons enrolled participants in the hundreds. Many clients who reach practitioners first met psychedelics through a storefront, a friend, a retreat or a ceremony.

Part 7.1 explains Canada’s national survey estimates, and Part 7.2 compares them with a study of adults in the United States. Parts 7.3 to 7.5 examine microdosing, retreats and ceremonies, and unlicensed storefronts. HSCI 402 develops drug checking and other harm reduction services.

Learning Objectives

  • 7.1 Describe how the Canadian Substance Use Survey measures psychedelic use, and interpret its 2023 and 2025 estimates with their confidence intervals and questionnaire changes.
  • 7.2 Compare Canadian survey estimates with Monitoring the Future estimates for adults in the United States, and explain why the two cannot be compared directly.
  • 7.3 Summarize what population surveys, observational studies and a placebo-controlled citizen-science study show about microdosing.
  • 7.4 Describe what surveys of retreat and ceremony participants report about substances, settings and adverse effects.
  • 7.5 Describe the growth of unlicensed psilocybin storefronts in Canada between 2024 and 2025, the health claims they make, and Health Canada’s stated position.

7.1 Measuring Psychedelic Use in Canada

National estimates of drug use come from population surveys, which ask a sample of people about their own use and then weight the answers to represent the population. Every estimate depends on who was asked, how the question was worded and how the drugs were grouped.

7.1.1 The Canadian Substance Use Survey

As of 2026, the Canadian Substance Use Survey (CSUS) is conducted every other year by Health Canada among people aged 15 and older in the ten provinces. It replaced the Canadian Alcohol and Drugs Survey (CADS), last conducted in 2019. The 2025 cycle collected data from 7 January 2025 to 5 January 2026 and obtained 36,061 respondents, weighted to represent 34.9 million people (Health Canada, 2026a). Recruitment used random digit dialling: more than 1.2 million telephone numbers were called, and 114,373 people agreed to receive a link to the survey. Because no list connects telephone numbers to people, Health Canada cannot adjust the results for non-response, and it warns that the margins of error may therefore appear smaller than they really are. To compensate, it treated a difference between years as real only when the confidence intervals did not overlap and other evidence supported it (Health Canada, 2026a).

The box below defines the terms needed to read the estimates that follow.

Reading a survey estimate

Past-year prevalence is the percentage of the population who report any use in the 12 months before the survey; lifetime prevalence is the percentage who report ever having used. A 95 percent confidence interval gives the range of values compatible with the data under the survey’s sampling assumptions; an estimate of 7.4 percent with an interval of 7.1 to 7.8 is more precise than one of 17.2 percent with an interval of 13.7 to 21.4, which comes from a much smaller subgroup. Weighting adjusts the sample so that its distribution by province, age and sex matches the population. Survey estimates also rest on self-report and on the categories in the questionnaire, so a change in wording can change the estimate without any change in behaviour.

Table 1.4 brings together the Canadian estimates for 2019, 2023 and 2025 and the United States estimates discussed in Part 7.2. The category names in the second column matter as much as the numbers.

Table 1.4. Past-year use of psychedelics or hallucinogens in Canadian and United States surveys, with the category each survey used.

Survey and yearCategory as defined by the surveyPast-year use
CADS 2019 (10,293 respondents aged 15+)Hallucinogens: drugs such as LSD, PCP and psilocybin, with salvia asked about separately2 percent overall; 6 percent at ages 20 to 24
CSUS 2023 (36,180 respondents)Psychedelics, asked as one grouped category (LSD, magic mushrooms or psilocybin, mescaline, peyote, 2C drugs or NBOMes)6 percent overall; 12 percent at ages 15 to 24
CSUS 2025 (36,061 respondents)Any psychedelic: psilocybin; LSD, mescaline, DMT, salvia, 2C drugs or NBOMes; analogues of LSD, psilocybin or DMT, asked separately7.4 percent overall (95 percent CI 7.1 to 7.8); psilocybin 7.2 percent; the LSD, mescaline, DMT and salvia group 1.4 percent; analogues 0.4 percent
Monitoring the Future, United States, 2022Hallucinogens; types reported included LSD, MDMA, mescaline, peyote, psilocybin and PCP8 percent at ages 19 to 30; 4 percent at ages 35 to 50
Monitoring the Future, United States, 2023Hallucinogens; types reported included LSD, mescaline, peyote, psilocybin and PCP9 percent at ages 19 to 30; 4 percent at ages 35 to 50

Sources: Health Canada (2021, 2024a, 2026a, 2026b); National Institute on Drug Abuse (2023); University of Michigan (2024). CI, confidence interval.

7.1.2 What the Canadian Estimates Show

Three findings stand out. First, in 2025 psychedelics were the most commonly used illegal drugs in Canada, and psilocybin was the most commonly used psychedelic: 43 percent of people who used any illegal or other substance of concern in the past year reported that psilocybin was the only one they used (Health Canada, 2026a). By comparison, past-year use of MDMA or similar drugs was about 2 percent, and use of ketamine or other dissociatives about 1 percent.

Second, the apparent rise from 6 percent in 2023 to 7 percent in 2025 must be read with care. Health Canada (2026a) notes that the increase may reflect the shift from a grouped question in 2023 to more specific questions in 2025. The lifetime estimates show why the caution is needed. Lifetime use rose from 16.4 percent in 2023 to 26.9 percent in 2025 in the Health Infobase data (Health Canada, 2026b). For that to reflect behaviour, about one in ten people aged 15 or older would have had to try a psychedelic for the first time within two years, which seems unlikely when 7.4 percent reported any use in the past year. A change in how the question was asked is the more plausible explanation. For the same reason, Health Canada advises against comparing CSUS results directly with the 2019 CADS, whose 2 percent estimate came from a different method and a category that included PCP.

Third, use is concentrated in some groups. Figure 1.4 shows past-year use by age in the two CSUS cycles.

0% 5% 10% 15% 9.8 8.1 15 to 17 12.5 13.1 18 to 24 12.7 12.8 25 to 34 7.4 10.6 35 to 44 3.6 6.4 45 to 54 1.7 3.8 55 to 64 0.7 1.1 65 or older Age group (years) 2023 2025 Percent, past 12 months
Figure 1.4. Past-year use of any psychedelic by age group, Canadian Substance Use Survey, 2023 and 2025 (percent of each age group). Data from the Health Infobase data tool (Health Canada, 2026b); the questionnaire changed between cycles, so differences between years may partly reflect wording.

In 2025, use was highest at ages 18 to 34, at about 13 percent, and lowest at age 65 or older, at about 1 percent. Between the two cycles the estimates rose most at ages 35 to 64, while the estimate for ages 15 to 17 fell from 9.8 to 8.1 percent, a change within the overlapping confidence intervals for that small group. Interactive 1.2 lets you explore the 2023 and 2025 estimates by other characteristics, with their confidence intervals.

Interactive 1.2
Explore past-year psychedelic use in the Canadian Substance Use Survey
Choose a measure and a characteristic. Each bar shows the weighted estimate, and the dark line across it shows the 95 percent confidence interval. Data: Health Canada, Health Infobase data tool for the Canadian Substance Use Survey (2023 and 2025 cycles), retrieved 17 October 2026.

In the 2025 data, past-year use was 8.6 percent among males and 6.2 percent among females, and about 17 percent among gender-diverse respondents and among people who identify as LGBTQ2+, estimates from smaller groups with wide intervals. Use was more than twice as common among people who rated their mental health as fair or poor (13.1 percent) as among those who rated it good, very good or excellent (6.0 percent). A cross-sectional survey cannot show which way this association runs. Some people may use psychedelics to manage distress, use may affect mental health, or shared conditions such as stress, trauma or discrimination may raise both; HSCI 214 examines those conditions. Use also occurs with other drugs: in 2025, 3 percent of the population reported using alcohol and psychedelics on the same occasion (Health Canada, 2026a).

Try it 1.3: Read the interval before the estimate

Use Interactive 1.2 to compare the 2023 and 2025 estimates for ages 15 to 17 and for ages 35 to 44. For each age group, note whether the two confidence intervals overlap, and decide how confidently you could tell a news reporter that use changed in that group. Then name one feature of the 2025 questionnaire that would make you cautious even where the intervals do not overlap.

The Canadian survey describes how many people use psychedelics in a given year. Part 7.2 sets these estimates beside data from the United States, where a longer series is available for adults.

7.2 Psychedelic Use Among Adults in the United States

The Monitoring the Future panel study, funded by the National Institute on Drug Abuse and conducted at the University of Michigan, follows a subset of people first surveyed in secondary school into adulthood and collects data each year by online and paper surveys (National Institute on Drug Abuse, 2023). The types of hallucinogen that participants reported included LSD, mescaline, peyote, psilocybin and PCP (University of Michigan, 2024), and the release on the 2022 data also listed MDMA (National Institute on Drug Abuse, 2023).

Among adults aged 19 to 30, past-year hallucinogen use rose from 3 percent in 2012 to 5 percent in 2017 and 8 percent in 2022; among adults aged 35 to 50, it rose from 1 percent or less in 2012 and 2017 to 4 percent in 2022 (National Institute on Drug Abuse, 2023). The 2023 estimates were 9 percent and 4 percent (University of Michigan, 2024), and the study reported that use reached the highest levels recorded in both age groups in 2024 (University of Michigan Institute for Social Research, 2025).

The two series cannot be compared number for number, because they cover different ages and years, use different categories (the American one includes PCP) and recruit respondents differently. Both nevertheless show use concentrated among young adults and becoming more common in mid-life. Part 7.3 turns to one particular way of using psychedelics.

7.3 Microdosing

Microdosing is the practice of regularly taking low doses of a psychedelic (Szigeti et al., 2021), at doses intended to be below the level that produces marked perceptual effects (Rootman et al., 2021). It differs from psychedelic-assisted therapy in nearly every respect described in Section 1: it is usually self-directed, repeated over weeks, and done without screening, supervision or integration.

7.3.1 How Common Is It?

Keyes, Terry-McElrath and Patrick (2026) analyzed 3,094 young adults aged 19 to 30 in the Monitoring the Future panel in 2022 and 2023. Past-year hallucinogen use was reported by 9.5 percent, and at least one occasion of microdosing in the past year by 6.8 percent, and the authors report that 73.1 percent of those who used hallucinogens microdosed at least once. People who microdosed reported much more use of alcohol, cannabis and other drugs than those who did not, which led the authors to raise concerns about the context in which microdosing occurs.

7.3.2 Why Do People Microdose, and Does It Work?

Rootman and colleagues (2021), a team based at the University of British Columbia, recruited 4,050 people who microdosed and 4,653 who did not through a mobile application, using psychedelic podcasts and online conference presentations to reach them. Psilocybin was the substance used by 85 percent of the microdosers, some of whom combined it with other products such as lion’s mane mushrooms, chocolate or niacin, a practice the authors call stacking. Health and wellness motives were the most common. Among participants who reported mental health concerns, those who microdosed reported lower levels of depression, anxiety and stress than those who did not. The design was cross-sectional and the sample self-selected, so the study cannot show that microdosing caused these differences; people who had a good experience may simply have been more likely to keep microdosing and to take part.

A placebo-controlled test of the same question used a different design. Szigeti and colleagues (2021) gave people who already microdosed online instructions for hiding their own doses in opaque capsules mixed with empty placebo capsules, so that they did not know which they were taking on any day. Of 1,630 people who signed up, 191 completed the study, which included a four-week dosing period. Psychological outcomes improved in the microdose group, but they improved in the placebo group as well, with no significant difference between the groups on the main outcomes, and the small differences found on some measures could be explained by participants correctly guessing which capsule they had taken. Lesson 5 examines this self-blinding design and the problem of guessing in detail. Section 4 uses both studies to show how design changes the strength of a claim.

A 2026 systematic review and meta-analysis by Meshkat and colleagues (2026) brought together 24 studies of microdosing in healthy adults. Observational studies reported improvements in mood that the authors judged likely to reflect expectancy or lifestyle, while randomized trials showed no clear benefit over placebo for depressive, anxiety or stress symptoms, and the authors judged the trial evidence inconclusive. The pooled analysis of randomized trials rested on two trials with 117 participants, and research on microdosing is still evolving.

7.4 Retreats and Ceremonies

A second setting is the retreat: an organized program, lasting from one day to more than a week, in which participants take a psychedelic in group sessions led by facilitators (Kettner et al., 2021). Retreats are distinct from Indigenous traditions such as the use of ayahuasca in Amazonian traditional medicine (Bouso et al., 2022), which have their own lineages and meanings; Lesson 2 describes those traditions and the harms that followed outside attention. An Indigenous-led global consensus process has raised concerns about cultural appropriation, the patenting of traditional medicines and the absence of Indigenous leadership in Western psychedelic research and practice, and it identified eight interconnected ethical principles: reverence, respect, responsibility, relevance, regulation, reparation, restoration and reconciliation (Celidwen et al., 2023). Lesson 12 returns to these principles.

Two large observational studies describe retreat and ceremony participants. Kettner and colleagues (2021) surveyed 886 people before and after a psychedelic retreat or ceremony. Psilocybin mushrooms or truffles accounted for 80 percent of the planned substances and ayahuasca for 16 percent, 40 percent of participants had never used a psychedelic before, and a sense of shared humanity during the ceremony correlated modestly with later gains in wellbeing (r = 0.22) and social connectedness (r = 0.25). Bouso and colleagues (2022) analyzed the Global Ayahuasca Survey of 10,836 people from more than 50 countries. Acute physical adverse effects, mainly vomiting, were reported by 69.9 percent, and 2.3 percent needed medical attention afterwards. Adverse mental health effects in the following weeks or months were reported by 55.9 percent, although about 88 percent of those respondents considered them part of a positive process of growth, and about 12 percent sought professional support. Physical adverse effects were more likely when ayahuasca was taken in an unsupervised context, and mental health adverse effects were less likely in religious settings.

Both studies relied on self-selected participants who answered online surveys, so they describe people who chose to take part and cannot estimate how common any outcome is among everyone who attends a retreat. Lesson 11 examines retreats operating in Canada. Part 7.5 turns to the setting that has grown most visibly in Canadian cities.

7.5 Unlicensed Psilocybin Storefronts

Between 2024 and 2025, shops selling psilocybin products to the public without any licence operated in several Canadian cities. Two studies by Matsukubo and colleagues provide systematic counts, and Health Canada has stated its position in writing.

7.5.1 Number, Location and Products

Matsukubo and colleagues (2025) used systematic web searches and media reports to identify 57 psilocybin dispensaries operating in Canada in May 2024, or 0.18 stores per 100,000 people aged 15 or older, in 15 of Canada’s 42 major urban centres; most were in Ontario and British Columbia. Of the 57, 61.4 percent belonged to chains. All of the stores examined sold dried mushrooms, 97.8 percent sold microdosing capsules, and most sold psilocybin chocolate and gummies, with 65.2 percent selling products that mimicked popular food brands. A repeat assessment found 75 stores by July 2025, or 0.24 per 100,000 (Matsukubo et al., 2026). Figure 1.5 shows that the growth came with rapid turnover.

May 2024: 57 stores July 2025: 75 stores 27 stayed 30 closed 27 stayed 48 opened stores open in both years Two chains ran 44 percent of stores in 2025; all but two stores were in Ontario or British Columbia. Bar heights are proportional to the number of stores.
Figure 1.5. Turnover of unlicensed psilocybin stores in Canada between May 2024 and July 2025: 30 of the 57 stores open in 2024 closed, 27 remained and 48 opened, giving 75. Data from Matsukubo and colleagues (2026).

Matsukubo and colleagues (2026) also found that 29.0 percent of residents of Vancouver lived within a ten-minute walk of a store, compared with 9.5 percent in Toronto, and that 49 percent of stores with online listings advertised other psychoactive substances, most often DMT.

7.5.2 Health Claims and Warnings

The 2024 study examined the stores’ websites. Of the 22 websites analyzed, 86.4 percent made at least one mental health claim, most often about anxiety (81.8 percent), depression (77.3 percent) and post-traumatic stress disorder (72.7 percent), and only two referred to a published study (Matsukubo et al., 2025). Warnings were rare where they would matter most: 9.1 percent warned against use while driving, 13.6 percent mentioned pregnancy, and 31.8 percent mentioned a history of psychosis, schizophrenia or bipolar disorder. The authors also noted that the websites very rarely mentioned that the benefits reported in trials came from psychedelic-assisted therapy. Section 4 examines two of these claims with the lesson’s checklist.

7.5.3 Health Canada’s Position

Case 1.2 describes a written statement of the federal position from March 2024.

Case 1.2: Health Canada writes to the City of Vancouver (March 2024)

In March 2024, after a panel of Vancouver city councillors voted to reissue a business licence to a psilocybin dispensary on West Broadway, Health Canada’s Controlled Substances and Opioid Response Directorate wrote to the city manager. The letter, dated 15 March 2024, stated that psilocybin mushrooms are controlled under the CDSA, that storefronts selling psilocybin to the general public are not authorized to do so and may be subject to law enforcement action, and that Health Canada considers that illegally operating storefronts pose a risk to the health and safety of Canadians (Health Canada, 2024b). Health Canada’s public page on psilocybin, modified in October 2025, adds that drugs produced illegally are not tested and may contain other dangerous substances (Health Canada, 2025).

Consider what the letter can and cannot do. It states the law and Health Canada’s view of the risk, but it does not itself close a store or revoke a municipal licence.

Public opinion is one input to the policy debate. In a web panel survey of 3,674 Canadian adults in March 2025, 79.1 percent were unfamiliar with psychedelic stores, respondents were evenly divided between closing the stores and keeping the unregulated status quo, and 66.6 percent supported authorizing sales under a regulatory framework (Gagnon et al., 2026). This course’s practice standard favours a regulated public health model with licensed providers and training standards; Lessons 11 and 12 present that position with the evidence and the counter-arguments, so that students can weigh the policy questions themselves.

Summary

This section showed that in 2025 psychedelics, mainly psilocybin, were the most commonly used illegal drugs in Canada, used in the past year by about 7 percent of people aged 15 or older, and that use was highest among young adults and among people who reported fair or poor mental health. It explained why questionnaire changes make the rise between 2023 and 2025 hard to interpret, and why Canadian and United States estimates cannot be compared directly. It described microdosing, retreats and ceremonies, and unlicensed storefronts as settings of use outside clinics. The evidence on microdosing comes from a national panel survey, a self-selected app-based survey and a placebo-controlled self-blinding study, and a 2026 review found the trial evidence inconclusive; the evidence on retreats comes from self-selected online surveys; and the storefront counts come from systematic web searches and media reports. The section also set out Health Canada’s written position on storefronts as of 2024 and 2025.

Section 4 asks how to judge the claims that circulate about these drugs, from storefront websites to company press releases, and offers a practical checklist for doing so.

Key Takeaways

  • 7.1 In the Canadian Substance Use Survey of 2025, 7.4 percent of people aged 15 or older (95 percent CI 7.1 to 7.8) reported past-year psychedelic use, mostly psilocybin, with use highest at ages 18 to 34 and among people who rated their mental health as fair or poor. The 2025 questionnaire asked about specific psychedelics where the 2023 one used a grouped question, so the apparent rise since 2023, and the jump in lifetime use from 16.4 to 26.9 percent, are hard to interpret. Health Canada also advises against direct comparison with the 2019 CADS.
  • 7.2 Monitoring the Future found past-year hallucinogen use of 8 percent at ages 19 to 30 and 4 percent at ages 35 to 50 in 2022, rising to record levels by 2024. The American and Canadian series cover different ages and years, use different categories (the American one includes PCP) and recruit differently, so they cannot be compared number for number, although both show use concentrated among young adults and becoming more common in mid-life.
  • 7.3 Microdosing is common among young adults who use hallucinogens and is usually self-directed, repeated and unsupervised. A large self-selected app study found lower depression, anxiety and stress among people who microdosed, but its cross-sectional design cannot show cause. In a placebo-controlled self-blinding study, microdose and placebo groups improved to a similar extent.
  • 7.4 Surveys of retreat and ceremony participants found that psilocybin and ayahuasca were the main substances, that many participants had never used a psychedelic before, and that acute physical adverse effects were common in the Global Ayahuasca Survey and more likely without supervision. These self-selected online samples cannot estimate how common any outcome is among everyone who attends a retreat, and Indigenous traditions have their own lineages and ethical principles distinct from commercial retreats.
  • 7.5 Unlicensed psilocybin storefronts in Canada grew from 57 in May 2024 to 75 by July 2025, with rapid turnover and most stores in Ontario and British Columbia. In 2024, 86.4 percent of store websites examined made mental health claims while warnings were rare. Health Canada wrote on 15 March 2024 that such storefronts are not authorized and pose a risk to health and safety.

Reflection

A hypothetical city councillor in British Columbia cites these figures. In the Canadian Substance Use Survey, past-year use of any psychedelic was 6.0 percent in 2023 and 7.4 percent in 2025 (95 percent confidence interval 7.1 to 7.8); Health Canada notes that the 2025 questionnaire asked about specific psychedelics where the 2023 questionnaire used one grouped question. Lifetime use was 16.4 percent in 2023 and 26.9 percent in 2025. In 2025, past-year use was 13.1 percent (95 percent confidence interval 12.0 to 14.4) among people who rated their mental health as fair or poor and 6.0 percent (5.8 to 6.3) among others. Unlicensed psilocybin stores in Canada rose from 57 in May 2024 to 75 in July 2025, and in 2024, 86.4 percent of 22 store websites claimed mental health benefits. The councillor says the numbers prove that storefronts caused a surge in psychedelic use and that people with poor mental health are being harmed by it. In 150 to 250 words, explain what these data can and cannot show, and name one additional source of evidence that would help answer the councillor’s question.

Model answer

The data show that psychedelic use, mostly of psilocybin, was common in Canada in 2025 and that unlicensed stores multiplied between 2024 and 2025. They do not show that stores caused an increase in use. The rise from 6.0 to 7.4 percent coincides with a change from a grouped question to specific questions, and Health Canada itself cautions that the change may explain part of the difference. The lifetime figure makes the point clearly: a jump from 16.4 to 26.9 percent in two years would require about one person in ten to try a psychedelic for the first time, which is implausible when 7.4 percent reported any past-year use. The survey also cannot link any individual’s use to a store.

The association with mental health is clear in these data, since the intervals do not overlap. Its direction is unknown. People in distress may seek out psychedelics, use may affect mental health, or stress, trauma or discrimination may raise both. The claims on store websites, which rarely cite evidence, are a separate concern.

Useful additional evidence would include future survey cycles that keep the 2025 wording, so that change can be measured on the same questions, combined with data linking store openings by area to local survey estimates or to emergency department visits over time.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: Why does Health Canada advise caution in interpreting the rise in past-year psychedelic use from 6 percent in 2023 to 7 percent in 2025?

Health Canada (2026a) notes that the increase may reflect the shift from grouped categories to more specific questions in 2025. The 2025 survey included people aged 15 and older, asked about dissociatives separately, and had 36,061 respondents, so options b to d are false.

Question 2: In the 2025 survey, past-year psychedelic use was 13.1 percent among people with fair or poor self-rated mental health and 6.0 percent among others. Which interpretation is best supported?

A cross-sectional survey shows an association. Distress may lead to use, use may affect mental health, or shared conditions may raise both. Options a and b each assume one direction. The intervals (12.0 to 14.4 and 5.8 to 6.3 percent) do not overlap, so option d is also wrong.

Question 3: What did Szigeti and colleagues (2021) find in their self-blinding study of microdosing?

Psychological outcomes improved in both the microdose and placebo groups, with no significant between-group differences on the main outcomes. Of 240 who started, 191 completed, so option b is wrong. Participants guessed correctly 72 percent of the time, above the roughly 62 to 63 percent expected by chance, so blinding was partly broken.

Question 4: What did Matsukubo and colleagues (2025) find about the websites of Canadian psilocybin dispensaries in 2024?

Of 22 websites, 86.4 percent made mental health claims, while 9.1 percent warned about driving and 13.6 percent mentioned pregnancy. Only two referred to a published study, and the authors noted that the websites very rarely mentioned psychedelic-assisted therapy. No store was licensed to sell psilocybin.
Section 4 of 5

Weighing Claims: The Renewed Research Era, the Hype Cycle and a Practical Checklist

⏱ Estimated reading time: 40 minutes
Section 4 of 5

Weighing Claims

The renewed research era, the hype cycle and a practical checklist.

The renewed research era

Attention has grown fast

9 → 601PubMed records with psilocybin in the title or abstract, 2000 to 2025
About 19-foldgrowth in psilocybin’s share of all PubMed records

Publication counts measure attention; 212 of the 601 records for 2025 were indexed as reviews (PubMed, searched October 2026). A 2022 phase 2 psilocybin trial was funded by the drug’s developer (Goodwin et al., 2022).

The hype cycle

From inflated expectations to realistic ones

Innovation trigger
Peak of inflated expectations
Trough of disillusionment
Slope of enlightenment
Plateau of productivity
Psychedelic research currently appears to be trapped in a hype bubble driven largely by media and industry interests.Yaden, Potash and Griffiths, JAMA Psychiatry, 2022
Case 1.3

An advisory committee reviews MDMA-assisted therapy

2 to 9vote that the evidence showed effectiveness (4 June 2024)
1 to 10vote that benefits outweighed risks

Members raised functional unblinding, possible bias and abuse potential; critics also cited unreported adverse events. The FDA declined approval in August 2024.

The checklist

Six questions for any claim

Design

Randomized trial, or survey and testimonial?

Comparator

Compared with placebo, a low dose or an established treatment?

Blinding

Did people know what they received?

Sample

How many people, and who?

Follow-up

Long enough to show benefits last?

Funding

Who paid, who reported, and what conflicts? (Lundh et al., 2017)

Applying it

Press releases, company reports and storefronts

  • Company-reported results, such as a June 2025 phase 3 announcement, are preliminary until a peer-reviewed report appears (Compass Pathways, 2025).
  • University press releases describe published work, but headlines can drop the caveats.
  • Storefront statements reproduced in one study cite no evidence at all (Matsukubo et al., 2025).
Next steps

Reflection, knowledge check and final assessment

Bring together definitions, measures of experience, patterns of use and the checklist.

Lesson 2: ceremony, Canadian psychiatry, prohibition and revival.

Introduction

Claims about psychedelics reach students, clients and policymakers from many directions: university press releases, company announcements to investors, news headlines, storefront websites and the accounts of friends. Some claims rest on randomized trials, some on surveys, and some on nothing that can be checked. This section gives a practical way to tell them apart.

Part 8.1 describes the growth of research and investment since 2000. Part 8.2 explains the hype cycle and why researchers in the field have warned about it. Part 8.3 sets out a six-item checklist, illustrated with studies from earlier sections, and Part 8.4 adds supporting questions and explains how to treat company-reported results and press releases. Part 8.5 asks you to apply the checklist to six real claims and to summarize one accurately, and the section closes with a task that draws on the whole lesson. Lessons 5 and 8 develop blinding and the interpretation of trial results in more depth.

Learning Objectives

  • 8.1 Describe the growth of psychedelic research since 2000 using publication counts, and identify the commercial interests that have accompanied it.
  • 8.2 Explain the hype cycle and the argument of Yaden, Potash and Griffiths (2022) that psychedelic research is caught in a hype bubble.
  • 8.3 Apply a six-item checklist (design, comparator, blinding, sample, follow-up and funding) to a claim about psychedelics or psychedelic-assisted therapy.
  • 8.4 Distinguish peer-reviewed trial reports from company-reported results, institutional press releases and marketing statements.
  • 8.5 Write a summary of a claim that states accurately how strong its evidence is.

8.1 The Renewed Research Era

After a long pause that Lesson 2 describes, research on psychedelics resumed in the 2000s and accelerated in the 2010s. Publication counts give one simple measure of that change.

Figure 1.6 shows the number of records in PubMed, the United States National Library of Medicine’s database of biomedical literature, with the word psilocybin in the title or abstract, for each year from 2000 to 2025. The search was run for this lesson on 17 October 2026.

0 200 400 600 9 2000 2005 11 2010 31 2015 125 2020 601 2025 Year of publication (PubMed records with psilocybin in the title or abstract)
Figure 1.6. PubMed records with psilocybin in the title or abstract, by year of publication, 2000 to 2025 (search psilocybin[tiab], run 17 October 2026). Darker bars mark 2020 onward. Counts include reviews and commentaries as well as studies.

The count stayed between 7 and 19 records a year until 2012, then rose to 31 in 2015, 125 in 2020 and 601 in 2025. Part of this growth reflects the growth of publishing in general: PubMed holds about 3.5 times as many records for 2025 as for 2000 (1,881,957 against 532,636). Even so, psilocybin records rose from about 1.7 per 100,000 PubMed records in 2000 to about 31.9 per 100,000 in 2025, so the topic’s share of the literature grew roughly nineteen-fold. A publication count measures attention, however, and attention is not evidence. In a search run on 18 October 2026, 212 of the 601 records for 2025 were indexed in PubMed as reviews, and 34 as clinical trials or randomized controlled trials.

Commercial interest grew alongside the research. A phase 2 trial of single-dose psilocybin for treatment-resistant depression, reported by Goodwin and colleagues (2022), was funded by the drug’s developer, COMPASS Pathfinder, and the developer, Compass Pathways, reported the result of a phase 3 trial (COMP005) to investors in a filing with the United States Securities and Exchange Commission in June 2025 (Compass Pathways, 2025). As of July 2026, the company was reported to have begun a rolling new drug application to the FDA, with completion expected in the fourth quarter of 2026 (PharmaTimes, 2026). In Canada, the retail market described in Section 3 is also commercial, with two chains running 44 percent of unlicensed psilocybin stores in 2025 (Matsukubo et al., 2026). Yaden, Potash and Griffiths (2022) note that news articles have mentioned the investment potential of psychedelics reaching billions of dollars. Funding from an interested party does not make a finding false. It does give some people a stake in how a finding is presented, which is why funding is one item in the checklist in Part 8.3.

8.2 The Hype Cycle

Rapid growth in attention and investment tends to produce a recognizable pattern. The technology research firm Gartner describes this pattern as a hype cycle with five phases, and researchers in the psychedelic field have used the idea to describe their own situation.

Figure 1.7 draws the cycle schematically. In Gartner’s description, an innovation trigger sparks early stories and media attention before usable products exist; a peak of inflated expectations brings success stories alongside many failures; a trough of disillusionment follows as trials and implementations underdeliver; a slope of enlightenment brings clearer understanding of where the technology helps; and a plateau of productivity arrives with mainstream adoption and clearer criteria for judging the technology (Gartner, n.d.).

Expectations and attention Time Innovation trigger Peak of inflated expectations Trough of disillusionment Slope of enlightenment Plateau of productivity
Figure 1.7. A schematic hype cycle with the five phase names used by Gartner (n.d.). The curve illustrates a pattern of expectations; it does not plot data, and placing any field on it is a judgement.

Yaden, Potash and Griffiths (2022), writing in JAMA Psychiatry, argued that psychedelic research “currently appears to be trapped in a hype bubble driven largely by media and industry interests.” They observed that media coverage had swung from alarm to excessive optimism, with articles describing psychedelics as a cure or a miracle drug, and that such extreme shifts in perception can obstruct rigorous science and reasonable clinical use. They asked researchers and clinicians to counter claims that the evidence does not support and to practise careful science communication. The hype cycle also predicts a trough, in which genuine but modest benefits may be dismissed along with exaggerated ones.

Case 1.3 describes one moment at which high expectations met a regulator’s review.

Case 1.3: An advisory committee reviews MDMA-assisted therapy (June 2024)

On 4 June 2024, the FDA’s Psychopharmacologic Drugs Advisory Committee reviewed the application for MDMA-assisted therapy for post-traumatic stress disorder. It voted 2 to 9 that the evidence showed the treatment was effective and 1 to 10 that its benefits outweighed its risks. Members cited functional unblinding (many participants could tell whether they had received MDMA), possible bias, unanswered questions about abuse potential (the regulatory term for a drug’s likelihood of non-medical use), and little evidence about the contribution of the psychological component, and some researchers also criticized the sponsor for adverse events that had not been reported (Pharmaceutical Executive, 2024). In August 2024 the FDA declined to approve the application and asked for another phase 3 trial (Fierce Biotech, 2024).

A phase 3 trial reported by Mitchell and colleagues (2021) had found a large difference from placebo. The committee’s concerns were about whether the design could show that the difference was caused by the drug. Lesson 9 examines the evidence, the decision and what followed.

Case 1.3 shows that a strong-looking result can still leave reviewers uncertain when blinding, adverse event recording and the role of each treatment component are in doubt. Part 8.3 turns those concerns into questions that anyone can ask of a claim.

8.3 A Checklist for Weighing Claims

The checklist in Table 1.5 asks six questions. None requires statistical training, and each can usually be answered from the abstract of a study or the text of a press release. The examples in the last column come from studies already discussed in this lesson.

Table 1.5. A six-item checklist for weighing a claim about psychedelics or psychedelic-assisted therapy, with an example of each item from this lesson.

ItemQuestion to askStronger evidenceWeaker evidenceExample from this lesson
DesignHow was the evidence produced?Randomized controlled trial, ideally replicatedOpen-label study, survey, case report or testimonialAn open-label pilot found 12 of 15 smokers (80 percent) abstinent at six months, measured as seven-day point prevalence abstinence, and its authors noted that the design does not allow definitive conclusions about efficacy (Johnson et al., 2014).
ComparatorCompared with what?Placebo, an active placebo, a low dose or an established treatmentNo comparison group, or a group chosen differentlyAgainst daily escitalopram, psilocybin did not differ significantly on the primary outcome (mean changes of −8.0 and −6.0 points, a difference of −2.0 points; 95 percent CI −5.0 to 0.9), although secondary outcomes favoured psilocybin without correction for multiple comparisons (Carhart-Harris et al., 2021).
BlindingDid participants and raters know who received what?Blinding maintained and checkedOpen-label, or blinding likely brokenIn the self-blinding study, participants guessed their capsule correctly 72 percent of the time, above the 62 to 63 percent expected from random guessing (Szigeti et al., 2021).
SampleHow many people, and who?Large enough for precise estimates; similar to the people the claim is aboutSmall or highly selected samplesThe brain-imaging study behind the “reset” claim had usable data from 16 of 19 patients and no control condition (Carhart-Harris et al., 2017).
Follow-upHow long were people followed?Long enough to show whether benefits lastDays or a few weeksA single 25 mg dose reduced depression scores at week 3, but sustained response at 12 weeks did not clearly support the primary result (Goodwin et al., 2022).
FundingWho paid, who reported, and are conflicts disclosed?Independent or disclosed funding; peer-reviewed reportSponsor’s own announcement; undisclosed interests; a seller’s claimThe microdosing app study disclosed that a co-author was an applicant on pending patents combining psilocybin, lion’s mane and niacin, one of the stacking practices it described (Rootman et al., 2021).

Each item has a reason behind it. Design matters because only randomization balances the known and unknown differences between groups. Comparators matter because people in comparison groups also improve, as both groups did in the escitalopram trial and in the self-blinding study, so a claim that a treatment helped needs a group that received something else. Blinding matters because expectations shape outcomes, especially self-rated ones, and Lesson 5 shows why blinding is hard when a drug’s effects are unmistakable. Sample size matters because studies with low statistical power tend to overestimate effects and are less likely to be reproduced (Button et al., 2013). Follow-up matters because a treatment given once must show that its benefit lasts. Funding matters because a Cochrane review found that industry-sponsored drug and device studies more often reported favourable efficacy results (risk ratio 1.27) and favourable conclusions (risk ratio 1.34) than studies with other sponsors (Lundh et al., 2017).

8.4 Supporting Questions and Company-Reported Results

The six items are not the only questions worth asking. The accordion below adds three more that often decide whether a sound study supports a particular claim.

Who was studied, and does the claim apply to them?v

Trial participants are screened, often have no psychotic disorder or serious heart disease, and receive psychological support. A result from such a trial says little about a person buying capsules in a storefront. Lesson 6 explains screening, and Lesson 8 examines the gap between trial and clinic populations.

What outcome was measured, and how?v

A claim about depression may rest on a self-rated questionnaire or on a clinician’s interview, and a difference of a few points on a 60-point scale may or may not matter to patients. Lesson 8 explains response, remission and the number needed to treat.

Where was the claim reported?v

A peer-reviewed trial report has been checked by independent reviewers and includes methods and limitations. A press release summarizes selected results, and a storefront website is advertising. The box after these questions explains how this course treats company-reported results.

Company-reported results and press releases

Companies often announce trial results before the full report is peer-reviewed, because they must inform investors. This course uses such announcements only for a company’s own unpublished trial results, and labels them as company-reported. Compass Pathways’ filing of June 2025, for example, reported that in its COMP005 trial, 258 participants with treatment-resistant depression received a single 25 mg dose of COMP360 or placebo, and that the mean difference in change on the Montgomery-Åsberg Depression Rating Scale (MADRS, scored from 0 to 60) at week 6 was −3.6 points (95 percent CI −5.7 to −1.5). The same filing stated that the FDA had not yet reviewed the data and that 26-week results were still to come (Compass Pathways, 2025). The company reported 26-week results for COMP005 in February 2026 (Compass Pathways, 2026) and six-month results from a second phase 3 trial, COMP006, in July 2026 (PharmaTimes, 2026), and both were again company-reported, so the evidence for this product was still evolving in October 2026. A reader should treat such numbers as the sponsor’s preliminary summary until the full report appears, and should check the date of every claim, because results in this field appear quickly.

University press releases are a different case. They describe peer-reviewed work, but they choose the framing, and a short headline can drop the caveats that the paper itself states.

With the checklist and its supporting questions in hand, Part 8.5 asks you to apply them to six real claims.

8.5 Applying the Checklist

Interactive 1.3 presents six claims that circulated between 2017 and 2025: two university press releases, one company announcement, one study title and two statements from Canadian psilocybin dispensary websites reproduced by Matsukubo and colleagues (2025). Each card summarizes the evidence behind the claim. Rate each checklist item, then compare your ratings with the analysis.

Interactive 1.3
Claim evaluator: six real claims against the checklist
For each claim, rate the six checklist items as “Meets the standard”, “Falls short” or “Cannot tell from the evidence given”. Then select “Compare with the analysis”. The analysis gives a reason for each rating; reasonable readers may disagree on borderline items, so read the reasons as well as the score.

Most claims fall short on several items, and the ones that fall short on most items are the least specific about their evidence. The two university press releases were hedged (“may”, “suggests”) and pointed to published studies whose authors listed their limitations; the storefront statements cited nothing. A careful summary carries the hedges forward and names the design.

Try it 1.4: Rewrite a headline

Rewrite the 2017 press-release headline, “‘Magic mushrooms’ may ‘reset’ the brains of depressed patients, study suggests,” as one accurate sentence of no more than 30 words. Your sentence should name the design, the number of patients and what was measured, using the evidence summarized on its card in Interactive 1.3.

One possible rewrite for Try it 1.4v

“In a small open-label study without a control group, brain scans of 16 patients with treatment-resistant depression changed after two psilocybin doses given with psychological support.” The sentence keeps the finding and states the three features that limit it: no comparison group, open-label dosing and a small sample.

Summary

This section showed that research on psilocybin has grown far faster than the biomedical literature as a whole since 2015, alongside substantial commercial interest, and explained the hype cycle that Yaden, Potash and Griffiths (2022) used to describe the field. It set out a six-item checklist (design, comparator, blinding, sample, follow-up and funding), with three supporting questions about population, outcome and venue, and applied it to six real claims, from storefront statements to a phase 3 announcement.

Applying this lesson: A storefront claim in British Columbia

A Canadian psilocybin dispensary website, reproduced by Matsukubo and colleagues (2025), states: “Psilocybin is a potent tool to cure severe cases of depression and PTSD.” Draw on all four sections to prepare a short evidence note for a hypothetical community health centre in British Columbia. Classify psilocybin and state how it acts (Section 1); explain how the trial use of psilocybin differed from buying it in a store, including the single supervised dose with psychological support in the trial of Goodwin and colleagues (2022) (Sections 1 and 3); say what the Canadian Substance Use Survey shows about who uses psilocybin and what Health Canada says about storefronts (Section 3); rate the claim on the six checklist items (Section 4); and name the lawful routes to psychedelic-assisted therapy in Canada (Section 1, 4.1 Where Psychedelic-Assisted Therapy Is Lawful in Canada). Avoid giving any advice about use.

The section reflection and knowledge check follow. The final assessment then asks you to bring together definitions, measures of experience, patterns of use and the checklist, and Lesson 2 traces the histories from which the current research era emerged.

Key Takeaways

  • 8.1 PubMed records with psilocybin in the title or abstract rose from between 7 and 19 a year until 2012 to 601 in 2025, a roughly nineteen-fold growth in the topic’s share of the literature. Commercial interest grew alongside, from developer-funded trials and filings to investors to retail chains running storefronts. A publication count measures attention, not evidence, and funding from an interested party gives some people a stake in how a finding is presented.
  • 8.2 Gartner’s hype cycle runs from an innovation trigger through a peak of inflated expectations and a trough of disillusionment to a slope of enlightenment and a plateau of productivity. Yaden, Potash and Griffiths (2022) argued that psychedelic research appears trapped in a hype bubble driven largely by media and industry interests, and the 2024 FDA advisory committee review of MDMA-assisted therapy shows high expectations meeting a regulator’s doubts about blinding, adverse events and the role of therapy.
  • 8.3 A claim can be weighed by asking six questions: how the evidence was produced (design), compared with what (comparator), whether people knew what they received (blinding), how many and who (sample), for how long (follow-up), and who paid and reported (funding). None requires statistical training, and each can usually be answered from an abstract or a press release.
  • 8.4 Who was studied, what outcome was measured and where the claim was reported often decide whether a sound study supports a particular claim. A peer-reviewed trial report includes methods and limitations; a company announcement is the sponsor’s preliminary summary and is labelled as company-reported; a press release chooses its framing; and a storefront website is advertising.
  • 8.5 Applied to six real claims, the checklist shows that most fall short on several items, and the claims that cite nothing fall short most often. An accurate summary carries the original hedges forward and names the design, the sample and what was measured, as in a rewrite of the 2017 “reset” headline that states it came from a small open-label study without a control group.

Reflection

A company press release from June 2025 is headlined “Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression.” The underlying facts are these: 258 participants at 32 sites were dosed, 171 with a single 25 mg dose of COMP360 and 87 with placebo, under double-blind conditions; the mean difference in change on the Montgomery-Åsberg Depression Rating Scale (scored 0 to 60) at week 6 was −3.6 points (95 percent confidence interval −5.7 to −1.5); 26-week results were not yet available at the time (the company reported them in February 2026, again before peer review); the results were reported by the company before peer review, and the FDA had not yet reviewed them. In an earlier phase 2 trial, a single 25 mg dose reduced scores by 6.6 points more than a 1 mg dose at week 3, but sustained response at 12 weeks did not clearly support that result (Goodwin et al., 2022). Rate each of the six checklist items (design, comparator, blinding, sample, follow-up and funding) as meeting the standard, falling short or impossible to judge from this information, giving one sentence of reasons for each, and then write a one-sentence headline that states the strength of the evidence accurately.

Model answer

Design meets the standard: a randomized, double-blind phase 3 trial is the strongest design available for this question. Comparator meets the standard, because placebo allows the drug’s effect to be separated from improvement over time and from attention. Blinding cannot be judged from the release: the design was double-blind, but a single strong psilocybin experience is easy to recognize, and the release does not report whether participants guessed their allocation. Sample meets the standard; 258 participants is large for this field, although they were screened adults with treatment-resistant depression. Follow-up falls short for this release, because the result rests on six weeks after one dose, and the phase 2 trial showed that early differences may not be sustained; the 26-week results that followed in February 2026 were also the company’s own report. Funding falls short as a source, because the sponsor reported its own result before peer review and regulatory review.

A more accurate headline would be: “In a company-reported, placebo-controlled trial of 258 adults with treatment-resistant depression, one dose of psilocybin reduced depression scores by 3.6 points more than placebo at six weeks; longer-term results were still to come.”

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: Johnson and colleagues (2014) reported that 12 of 15 participants were abstinent from smoking at six months (seven-day point prevalence abstinence). Which checklist item most limits this claim?

The authors themselves stated that the open-label design does not allow definitive conclusions about efficacy: without a comparison group, the 80 percent seven-day abstinence rate cannot be attributed to psilocybin. Six months is a reasonable follow-up for a pilot, a sample of 15 is small for a test of efficacy, and nothing in the lesson suggests tobacco industry funding.

Question 2: What did Lundh and colleagues (2017) report in their Cochrane review of industry sponsorship?

The review found that industry-sponsored studies more often reported favourable efficacy results (risk ratio 1.27) and favourable conclusions (risk ratio 1.34). Option a reverses the direction. Harms results were similar, with very low quality evidence, so option d is not supported.

Question 3: According to Yaden, Potash and Griffiths (2022), what has largely driven the hype bubble around psychedelic research?

The authors wrote that psychedelic research appears to be trapped in a hype bubble driven largely by media and industry interests. No psychedelic product had been approved before trials were complete, and reports of harm would push expectations down. Option d misrepresents Indigenous communities, many of whom have raised concerns about outside appropriation (Celidwen et al., 2023).

Question 4: A press release states that a company’s phase 3 trial met its primary endpoint, with a 3.6-point difference from placebo at week 6. How does this course treat such a result?

The course uses company announcements only for a company’s own unpublished results and labels them as company-reported (8.4 Supporting Questions and Company-Reported Results). Randomization is a strength, but it does not settle blinding, follow-up or the details of analysis, so option b overstates the evidence. Option c dismisses real data, and an endpoint is not an approval; the filing itself noted that the FDA had not reviewed the data.
Section 5 of 5

Final Assessment

⏱ Estimated time: 30 minutes

Bringing It All Together

This lesson set out the vocabulary and the habits of evidence that the rest of the course depends on. Section 1 defined the classic psychedelics by their action at the serotonin 2A receptor and separated them from the entactogen MDMA, the dissociative ketamine and the atypical agents ibogaine and salvinorin A, then showed that Canadian law and national surveys sort the same drugs differently. It defined psychedelic-assisted therapy as a phased process in which one or a few supervised doses sit inside screening, preparation and integration, and it named the routes through which that therapy can lawfully take place in Canada.

Section 2 explained how researchers measure the experience with the 5D-ASC, the MEQ30, the Ego Dissolution Inventory and the Challenging Experience Questionnaire, and how user-reported sources such as PsychonautWiki describe it. Section 3 turned to the people who use psychedelics, from the 2.6 million Canadians reporting past-year use in 2025 to microdosing, retreats and the unlicensed storefronts documented in 2024 and 2025. Section 4 placed these findings in the context of a fast-growing and commercially interested field and gave a six-item checklist for weighing any claim.

The final reflection and knowledge assessment below ask you to combine these parts: to classify a drug, describe what its effects are and how they are measured, place a claim in the context of real patterns of use, and judge the evidence behind it.

Key Takeaways from this lesson

  1. Classic psychedelics, including psilocybin, LSD, DMT and mescaline, form a pharmacological class because they act as agonists or partial agonists at serotonin 2A receptors, even though they come from three chemical families. MDMA, ketamine, ibogaine and salvinorin A produce related experiences through different primary mechanisms, so findings about one drug cannot be transferred to the others.
  2. The Controlled Drugs and Substances Act and national surveys sort these drugs into categories that do not follow pharmacology, and readers need to know which system a source uses.
  3. Psychedelic-assisted therapy places one or a few supervised dosing sessions inside a course of screening, preparation and integration, which makes it a different model of treatment from a daily medication and from supervised esketamine.
  4. As of October 2026, psychedelic-assisted therapy with psilocybin or MDMA can lawfully take place in Canada only through clinical trials, the Special Access Program or subsection 56(1) exemptions.
  5. Psychedelics change perception, emotion, cognition and the sense of self, and research scales such as the 5D-ASC, MEQ30, Ego Dissolution Inventory and Challenging Experience Questionnaire make these experiences comparable across doses, drugs and people; the MEQ30 criterion for a complete mystical experience requires at least 60 percent of the maximum on every factor.
  6. The items of research scales reflect researchers’ choices and their ratings are retrospective, while user-reported sources such as PsychonautWiki, Erowid and TripSit document vocabulary, experiences and harm reduction information and are never evidence of how often an effect occurs or that a drug is effective or safe.
  7. About 7 percent of people in Canada aged 15 or older reported past-year psychedelic use in 2025, mostly psilocybin, and changes in the questionnaire make the apparent rise since 2023 difficult to interpret. Evidence on microdosing and retreats comes mainly from surveys and one placebo-controlled self-blinding study, in which microdose and placebo groups improved to a similar extent, and a 2026 review found the trial evidence on microdosing inconclusive; the storefront counts come from systematic web searches.
  8. Attention to psychedelic research has grown fast enough to fit the hype cycle, and a claim about psychedelics can be weighed by asking about its design, comparator, blinding, sample, follow-up and funding, and by checking whether it is peer-reviewed, company-reported or a seller’s statement.

Core Concepts Reviewed

Section 1: classic serotonergic psychedelics, the 5-HT2A receptor, entactogens, dissociatives, atypical agents, prodrugs, Canadian drug schedules and survey categories, psychedelic-assisted therapy and its phases, and the authorized routes of access in Canada.

Section 2: perceptual, emotional, cognitive and self-related effects, the 5D-ASC and its lower-order scales, the MEQ30 and the complete mystical experience criterion, the Ego Dissolution Inventory, the Challenging Experience Questionnaire, and user-reported sources and their limits.

Section 3: past-year and lifetime prevalence, confidence intervals, weighting and non-response, the Canadian Substance Use Survey and Monitoring the Future, microdosing and self-blinding, retreats and the Global Ayahuasca Survey, and unlicensed psilocybin storefronts.

Section 4: the growth of psychedelic research, commercial interests, the hype cycle, the six-item checklist of design, comparator, blinding, sample, follow-up and funding, functional unblinding, and company-reported results.

The final reflection asks you to respond to a set of everyday claims using evidence from all four sections.

Reflection

A hypothetical friend in Vancouver tells you three things: that a store near their home sells psilocybin microdosing capsules “for anxiety”, that “psychedelics are basically antidepressants that work faster”, and that “everyone is doing it now”. Write 200 to 300 words that respond respectfully and accurately, drawing on all four sections. Use these facts: psilocybin is converted to psilocin, which activates serotonin 2A receptors; in trials, psilocybin was given once or twice in a supervised session with psychological support to screened participants (Goodwin et al., 2022; Carhart-Harris et al., 2021); in the Canadian Substance Use Survey of 2025, 7 percent of people aged 15 or older reported past-year psychedelic use, with about 13 percent at ages 18 to 34; Health Canada wrote on 15 March 2024 that storefronts selling psilocybin are not authorized under the Controlled Drugs and Substances Act; in a self-blinding study, microdose and placebo groups improved to a similar extent (Szigeti et al., 2021); a 2026 meta-analysis found no clear benefit of microdosing over placebo in randomized trials with healthy adults (Meshkat et al., 2026); user reports cannot establish how often an effect occurs or that a product is effective or safe; and, as of October 2026, the authorized routes in Canada are clinical trials, the Special Access Program and subsection 56(1) exemptions. Do not give advice about using any drug.

Model answer

I would start by agreeing that interest in psilocybin is real and that many people are curious about it. Psilocybin is converted in the body to psilocin, which activates serotonin 2A receptors. That is a different mechanism from an antidepressant such as escitalopram, which is taken every day. In the trials that reported benefits, psilocybin was given once or twice to screened participants in a long supervised session, with psychological support before and after. The support, screening and follow-up were part of the treatment, and none of that comes with a capsule bought in a store.

On microdosing for anxiety, one controlled study had people who already microdosed mix their capsules with placebos without knowing which was which. Both groups improved to a similar degree, which suggests that expectations explain much of the reported benefit, and a 2026 review of randomized trials in healthy adults also found no clear benefit over placebo, although research on microdosing is still evolving. Reports from other people who microdose show what people experience, but they cannot show how often a benefit occurs or that a product is safe, and Health Canada notes that illegally produced drugs are not tested.

“Everyone” is also an overstatement. In the 2025 national survey, about 7 percent of people aged 15 or older reported using a psychedelic in the past year, and about 13 percent of people aged 18 to 34. That is a substantial number, but it is a minority.

Finally, the store is not authorized: Health Canada wrote in March 2024 that storefronts selling psilocybin are not permitted under the Controlled Drugs and Substances Act. As of October 2026, psilocybin-assisted therapy can lawfully take place in Canada through clinical trials, the Special Access Program or a section 56 exemption, and anyone concerned about anxiety can start by speaking with their own health care provider about the options available to them.

Minimum 30 characters required.

✓ Reflection saved

Final Knowledge Assessment

Final Assessment, this lesson: Psychedelics and Psychedelic-Assisted Therapy: Definitions, Effects and How to Weigh Claims (15 Questions)

Question 1: A hypothetical news story says that ketamine, MDMA and psilocybin “all work by flooding the brain with serotonin.” Which correction is accurate?

Each drug has a different primary mechanism (Table 1.1): psilocin is a 5-HT2A agonist, MDMA releases serotonin through the serotonin transporter, and ketamine inhibits NMDA glutamate receptors. Option b is tempting because two of the three involve serotonin, but ketamine’s main action is on glutamate receptors.

Question 2: Which pairing of a substance with its status under the Controlled Drugs and Substances Act (consolidated to 30 September 2026) is correct?

MDMA is listed in Schedule I among the amphetamines. Psilocybin is in Schedule III, ibogaine is not listed in the Act and is on the Prescription Drug List, and the Schedule III entry for mescaline expressly excludes peyote.

Question 3: Beyond any change in behaviour, why does the 2019 Canadian Alcohol and Drugs Survey estimate of hallucinogen use differ in meaning from the 2025 Canadian Substance Use Survey estimate of psychedelic use?

The 2019 hallucinogen category covered drugs such as LSD, PCP and psilocybin, and Health Canada advises against comparing the two surveys because their methods differ. The 2019 survey included all ages 15 and older, and psilocybin was the most common psychedelic in 2025.

Question 4: Which feature of psychedelic-assisted therapy does the protocol of Mitchell and colleagues (2021) illustrate?

The trial combined three preparatory sessions, three eight-hour experimental sessions about four weeks apart and nine 90-minute integration sessions. Option d describes supervised esketamine, which the lesson contrasts with psychedelic-assisted therapy.

Question 5: In the pooled data of Studerus and colleagues (2010), which lower-order scales correlated most strongly with the dread of ego dissolution dimension?

Impaired control and cognition (0.91) and anxiety (0.86) correlated most strongly with dread of ego dissolution (Figure 1.3). Unity, blissful state, spiritual experience and insightfulness grouped with oceanic boundlessness, and the imagery scales with visionary restructuralization.

Question 6: Nour and colleagues (2016) found that Ego Dissolution Inventory scores rose with dose for psychedelics but not for cocaine or alcohol. What does this finding mainly support?

A dose-response relationship specific to psychedelics supports the claim that ego dissolution belongs to psychedelic states. The finding says nothing about later benefit or physical safety, and the Challenging Experience Questionnaire measures a different construct.

Question 7: A hypothetical client says PsychonautWiki describes an effect called “thought loops” and asks whether it is common. Which reply is most accurate?

User-reported sources document what people describe without a denominator, so they cannot establish frequency (Section 2, 6.2 User-Reported Sources). The MEQ30 measures mystical-type experience and was never meant to list every effect, and the index does not restrict thought loops to MDMA.

Question 8: Which statement about the 2025 cycle of the Canadian Substance Use Survey is correct?

Because random digit dialling cannot link numbers to people, Health Canada could not adjust for non-response and warned that the margins of error may appear smaller than they really are. Psychedelics, mainly psilocybin, were the most used illegal drugs, and the survey covered ages 15 and older.

Question 9: What did Keyes, Terry-McElrath and Patrick (2026) report about microdosing among United States adults aged 19 to 30 in 2022 and 2023?

Microdosing was reported by 6.8 percent, about 1 in 15, and by 73.1 percent of those who used hallucinogens. People who microdosed reported more use of alcohol, cannabis and other drugs than other young adults, which is why option c is wrong.

Question 10: Rootman and colleagues (2021) found lower depression and anxiety among microdosers with mental health concerns. Which checklist items most limit a causal reading of this finding?

A single cross-sectional measurement of self-selected groups cannot show that microdosing caused the difference. The sample was large (8,703), the study disclosed funding from the app company, no placebo was used, and no one was randomized.

Question 11: Which finding did Bouso and colleagues (2022) report from the Global Ayahuasca Survey?

Physical adverse effects were associated with taking ayahuasca in a non-supervised context. Acute physical effects, mainly vomiting, were reported by 69.9 percent; about 88 percent of those with adverse mental health effects saw them as part of growth; and religious settings were associated with fewer mental health adverse effects.

Question 12: At the FDA advisory committee meeting of June 2024 (Case 1.3), members were concerned that many participants could tell whether they had received MDMA. Which checklist item does this concern address most directly?

Knowing one’s allocation is functional unblinding, a failure of the blinding item. It allows expectations to influence outcomes, which is why the committee questioned whether the large difference from placebo could be attributed to the drug.

Question 13: What did Health Canada’s letter of 15 March 2024 to the City of Vancouver state?

The letter stated that psilocybin is controlled under the Controlled Drugs and Substances Act, that storefronts selling it to the public are not authorized and may face enforcement, and that illegally operating storefronts pose a risk to health and safety. As of October 2026, psilocybin remains in Schedule III, and no product type is exempt.

Question 14: Which change between the 2023 and 2025 survey cycles best shows why an estimate must be read alongside the questionnaire that produced it?

A rise of more than ten points in lifetime use within two years is implausible as a change in behaviour, and it coincided with the move from a grouped question to specific questions. Use at ages 18 to 34 stayed near 13 percent, past-year use rose from 6.0 to 7.4 percent, and psilocybin was asked about in 2025.

Question 15: Which summary of the June 2025 COMP005 announcement best applies the lesson’s checklist?

The accurate summary names the design, the comparator, the sample, the short follow-up and the company-reported status. Option a claims a cure, option b dismisses a statistically significant result without evidence about its clinical meaning (Lesson 8), and option d invents peer review and a 26-week result that the June 2025 announcement did not report.
✦ Complete the final reflection above before submitting

Congratulations!

You have successfully completed this lesson: Psychedelics and Psychedelic-Assisted Therapy: Definitions, Effects and How to Weigh Claims.

You can now classify psychedelics and related drugs by mechanism, legal schedule and survey category; describe psychedelic-assisted therapy and the lawful routes to it in Canada; explain how psychedelic experiences are measured and what user-reported sources can establish; interpret Canadian and United States survey data on psychedelic use; and weigh a claim about psychedelics against a six-item checklist.

Lesson 2 turns to history: Indigenous and ceremonial traditions and their colonial suppression, mid-century psychiatric research in Saskatchewan and British Columbia, coercive experimentation and prohibition, and the revival that produced the research era examined here.

Continue to Lesson 2 →
Reference

Glossary: Key Terms, People & Frameworks

📚 Reference page, available throughout the lesson

Definitions of the terms, measures, people and frameworks introduced in this lesson, in the sense in which this course uses them.

Core Concepts
Classic psychedelic A drug, such as psilocybin, LSD, DMT or mescaline, that produces its main effects as an agonist or partial agonist at serotonin 2A receptors; also called a serotonergic psychedelic (Nichols, 2016).
Serotonin 2A (5-HT2A) receptor A serotonin receptor found on cortical pyramidal neurons, among other places; its activation is essential for the subjective effects of classic psychedelics (Kelmendi et al., 2022).
Agonist A molecule that binds to a receptor and activates it, as the body’s own neurotransmitter would; a partial agonist activates it less fully.
Prodrug A compound that becomes active only after the body converts it; psilocybin is converted to psilocin in the gut lining and liver.
Atypical agent In this course, a drug such as ibogaine or salvinorin A that produces psychedelic-like experiences through targets other than those of the classic psychedelics, MDMA or ketamine.
Entactogen A class name proposed by David Nichols in 1986 for MDMA and similar drugs, from roots meaning “touching within”; empathogen is a related term proposed by Ralph Metzner.
Dissociative A drug that produces a sense of detachment from the body or surroundings; ketamine, which inhibits NMDA glutamate receptors, is the main clinical example.
NMDA receptor A type of glutamate receptor; ketamine’s anaesthetic effects are attributed to its inhibition (Zanos et al., 2018).
Kappa-opioid receptor An opioid receptor subtype; salvinorin A is a selective agonist at it (Roth et al., 2002), and noribogaine, a metabolite of ibogaine, also acts there.
Hallucinogen (as a category) A term emphasizing perceptual effects, used in this course only as a legal or survey category; the 2019 Canadian survey’s hallucinogen category included the dissociative PCP.
Psychedelic-assisted therapy A structured psychotherapeutic process in which one or a few supervised doses of a psychedelic are given within a course of screening, preparation and integration.
Integration The phase of psychedelic-assisted therapy after a dosing session, in which the person works with the therapists to understand and apply the experience; in the MDMA trial of Mitchell and colleagues (2021), three integration sessions followed each dosing session.
Ego dissolution A temporary loss of the usual sense of being a separate self, measured by the Ego Dissolution Inventory and described by Nour and colleagues (2016) as a key feature of psychedelic experience.
Mystical-type experience An experience combining unity, sacredness, a sense of encountering truth, positive mood, transcendence of time and space and ineffability, following an account by W. T. Stace (1960) as described by Barrett and colleagues (2015).
Complete mystical experience A research classification in which every factor of the MEQ30 scores at least 60 percent of its maximum; 94 of 184 psilocybin sessions met it in the validation data (Barrett et al., 2015).
Challenging experience An episode of intense fear, grief, confusion or distress during a psychedelic experience; people who use psychedelics often call it a “bad trip”.
User-reported source A collection of accounts written or edited by people who use drugs, such as PsychonautWiki or Erowid, useful for vocabulary and range of experiences and never as evidence of efficacy or safety.
Past-year prevalence The percentage of a population reporting any use in the 12 months before a survey; lifetime prevalence is the percentage reporting ever having used.
Random digit dialling A survey recruitment method that calls randomly generated telephone numbers; because numbers cannot be linked to people, results cannot be adjusted for non-response.
Microdosing The practice of regularly taking low doses of a psychedelic, intended to be below the level that produces marked perceptual effects, usually without clinical supervision.
Self-blinding A citizen-science design in which participants randomize and conceal their own active and placebo capsules, used by Szigeti and colleagues (2021) to study microdosing.
Functional unblinding A situation in which participants or raters can tell which treatment was received from its effects, despite a formally blinded design; Lesson 5 develops the concept.
Open-label study A study in which participants and investigators know which treatment is given; such a study cannot separate a drug’s effect from expectations.
Hype cycle A model, popularized by the research firm Gartner, in which attention to a new technology rises to a peak of inflated expectations, falls into a trough of disillusionment and later stabilizes.
Company-reported result A trial result announced by its sponsor, usually to investors, before peer review; this course labels such results and treats them as preliminary.
Conflict of interest A financial or other interest that could influence how a study is designed, analyzed or reported; industry-sponsored drug studies more often report favourable results (Lundh et al., 2017).
Frameworks & Tools
5D-ASC The five-dimensional altered states of consciousness questionnaire: 94 items on visual analogue scales covering oceanic boundlessness, dread of ego dissolution, visionary restructuralization, auditory alterations and vigilance reduction, with 11 lower-order scales (Studerus et al., 2010).
MEQ30 The revised 30-item Mystical Experience Questionnaire, with four factors (mystical, positive mood, transcendence of time and space, ineffability) rated from 0 to 5 (Barrett et al., 2015).
Ego Dissolution Inventory (EDI) An 8-item visual analogue scale measuring ego dissolution, validated in an internet survey of 691 people (Nour et al., 2016).
Challenging Experience Questionnaire (CEQ) A 26-item questionnaire with seven factors (grief, fear, death, insanity, isolation, physical distress and paranoia) describing difficult psychedelic experiences (Barrett et al., 2016).
PsychonautWiki Subjective Effect Index A user-contributed reference of subjective drug effects, organized under headings such as visual, cognitive and physical effects and derived mainly from contributors’ experiences and online reports.
Canadian Substance Use Survey (CSUS) Health Canada’s survey of substance use among people aged 15 and older in the provinces, conducted every other year as of 2026; its 2025 cycle had 36,061 respondents.
Special Access Program (SAP) A Health Canada program through which regulated health care practitioners can request non-marketed drugs, including psilocybin, for patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable or are unavailable (Canada Gazette, 2025; Health Canada, 2025). Since 1 October 2026 the Controlled Substances Regulations allow a practitioner named in a letter of authorization to administer or provide a restricted drug such as psilocybin or MDMA.
Subsection 56(1) exemption An exemption from some or all of the Controlled Drugs and Substances Act that the Minister of Health may grant when it is necessary for a medical or scientific purpose or otherwise in the public interest; one of the three routes to psilocybin that Health Canada names as of October 2026.
Key People
Humphry Osmond The psychiatrist who proposed the word psychedelic, from the Greek for “mind manifesting”, in 1956 correspondence with Aldous Huxley and introduced it publicly in 1957 (Kelmendi et al., 2022; Dyck, 2019); Lesson 2 describes his work.
David E. Nichols A researcher, affiliated with the University of North Carolina’s Eshelman School of Pharmacy at the time, whose 2016 review in Pharmacological Reviews defines classic psychedelics by their 5-HT2A agonism; he proposed the term entactogen in 1986.
Frederick S. Barrett A researcher who, at the Johns Hopkins University School of Medicine, led the validation of the MEQ30 (2015) and the development of the Challenging Experience Questionnaire (2016).
Balázs Szigeti A researcher who led the 2021 self-blinding citizen-science study of microdosing at Imperial College London’s Centre for Psychedelic Research.
David B. Yaden First author, with Potash and Griffiths, of the 2022 JAMA Psychiatry viewpoint warning that psychedelic research is caught in a hype bubble.
No matching entries. Try a different search term.